Dr. Malone was so damn right when he said we’re barely scratching the surface on the biolabs topic.
And so was I when I insisted you should pay special attention to the research on insects that’s been going on not only in the US funded labs in Ukraine and Georgia, but all over the world, including US soil.

UNIVERSITY OF SOUTH CAROLINA WELCOMES YOU TO YOUR WORST NIGHTMARE YOU HAVEN’T EVEN FATHOMED YET

THE CHERNOBYL & FUKUSHIMA RESEARVH INITIATIVE BY DTRA, THE US AGENCY FUNDING THE UKRAINE BIOLABS

SUMMARY OF THE INITIATIVE AND ITS RESEARCH

                                           (for a PDF version of this text click here)

The Chernobyl Research Initiative began formal research activities in Ukraine in 2000, Belarus in 2005, and Fukushima, Japan, in July, 2011. To date, the group has conducted more than 35 research expeditions to Chernobyl and 16 expeditions to Fukushima.

USC’s Chernobyl Research Initiative was the first and currently is the only research group to utilize a multidisciplinary approach to address the health and environmental outcomes of radiation effects in free-living natural populations. This has permitted the investigation of both acute (short term) and chronic (long term and multi-generational) exposures.

The Chernobyl Research Initiative is also currently the only research team studying plants and animals in both Chernobyl and Fukushima.

Key funding sources have included the Samuel Freeman Charitable Trust, the CNRS (France), the National Science Foundation, and the National Geographic Society. Subsequently, additional funding sources have included the Civilian Research Development Foundation (CRDF), the National Institutes of Health (NIH), Qiagen GmbH, the Fulbright Foundation, the University of South Carolina Office of Research and the College of Arts and Sciences, the Academy of Finland, and gifts from private citizens.

To date, more than 90 scientific publications have resulted from this initiative, most in the past 10 years (see link above for publications). This research has been highlighted in many newspaper reports and television programs including the New York Times, The Economist, Harpers, the BBC, CNN, CBS’s 60 Minutes, and Miles O’Brian of PBS News Hour (see links above for media coverage).

The team has pioneered the use of ecological, genetic and dosimetric technologies in order to unravel the health and environmental consequences of chronic low-dose exposure resulting from the Chernobyl and Fukushima disasters. These have included massively replicated ecological censuses of natural populations of birds, mammals and insects to investigate population and demographic effects; DNA sequencing and genotoxicity testing to assess short and long term genetic damage to individuals living in the wild; and the use of miniature dosimeters attached to wild animals and field measurements of whole body burdens of radioisotopes in birds and mammals to obtain accurate estimates of realized external and internal radiation doses to animals living under natural conditions. Recently, the group has expanded to include epidemiological and genetic studies of human populations (especially children) living in Chernobyl-affected regions of Ukraine.

Key results include the discovery of tumors, cataracts and damaged sperm in birds from high radiation areas of Chernobyl, and impacts on biodiversity in Fukushima. Exciting new results include the discovery that some species of birds may have developed resistance to the effects of radiation and effects on neurological development in small mammals in both Chernobyl and Fukushima.

These two disasters differ in the time since the events, and the amount and diversity of radionuclides that were released, although the predominant source of radiation is cesium-137 in both locations.

DTRA in Fukushima – Operation Tomodachi by the agency funding Ukrainian biolabs

We are seeking funding to support the following ongoing and planned future research activities of the Chernobyl + Fukushima Research Initiative:

1)Continued monitoring of Fukushima populations of birds, small mammals, and insects in order to test for changes in population sizes (abundances) and numbers of species (biodiversity) through time.

2)Continued monitoring of barn swallows and rodents (mice and voles) populations for cancers, survival, reproduction, and genetic damage in Fukushima and Chernobyl (in collaboration with the CNRS, France, Rikkyo University, Tokyo, the Wild Bird Society of Japan, the National Institute of Forestry, Japan, and the University of Jyvaskyla, Finland).

3)Initiate a new project to study effects of radiation on tree growth and soil microbial activity in Fukushima (in collaboration with Chubu University, Nagoya, Japan).

4)Initiate a new project to investigate effects of radiation growth, fertility, and genetic damage in cows living in highly radioactive regions of Fukushima (in collaboration with the Fukushima Cattle Ranchers Association).

5)Initiate a new project to examine mutation rates in humans using whole genome DNA sequencing. Initially this project will focus on families living in contaminated regions of Ukraine. The project is in collaboration with the Montreal Neurological Institute and Hospital at McGill University, the Center of Radiological Research at Columbia University, and the Institute for Radiation Medicine in Kiev, Ukraine.

6)Continued development of new methods for measurement of dose and genetic damage in wild populations of animals.

7)Coordination of an international consortium of independent scientists to provide unbiased evidenced-based information concerning the health and environmental risks related to nuclear accidents. This group will compile, evaluate, and interpret the current scientific and medical literature and develop a literature suitable for public distribution via the print and internet media, as well as public presentations in Japan and internationally.

Highlights from research published by the Chernobyl Research Initiative include the following:

•Population sizes and numbers of species (i.e. biodiversity) of birds, mammals, insects, and spiders are significantly lower in areas of high contamination in Chernobyl.

•For many birds and small mammals, life spans are shorter and fertility is depressed, in areas of high contamination.

•In Fukushima, only birds, butterflies, and cicadas showed significant declines during the first summer following the accident. Other groups were not negatively affected.  Now, five years later, effects on birds have increased.

•There is considerable variability among species in their sensitivity to radionuclides. Many species are not affected, and a few species even appear to increase in numbers in areas of high contamination in both Chernobyl and Fukushima, presumably in response to competitive release (i.e. more available food and shelter) and fewer predators.

•Many species show evidence of genetic damage stemming from acute exposures and the differences observed between Fukushima and Chernobyl suggests some species may show the consequences of mutation accumulation over multiple generations.

•Some individuals and species show no evidence of genetic damage in relation to radiation exposure and some even show evidence of evolutionary adaptation to the effects of radiation through increased antioxidant activity, which may provide protection against ionizing radiation.

•The bird species that are most likely to show declines in numbers in response to radiation are those that historically have shown increased mutation rates for other reasons possibly related to DNA repair ability or reduced defenses against oxidative stress.

•Deleterious effects of radiation exposure seen in natural populations in Chernobyl include increased rates of cataracts, tumors, growth abnormalities, deformed sperm, and albinism. 

Maps of Contaminated regions of Fukushima (left), Ukraine, Belarus and Russia (right), and Europe (below). Fukushima map courtesy of Shane Welch; other maps courtesy of the European Union.

•Neurological development is impacted as evidenced by depressed brain size in both birds and rodents and consequent effects on cognitive ability and survival have been demonstrated in birds.

•Tree growth and microbial decomposition in the soil are also depressed in areas of high radiation. 

•In Fukushima, the first signs of developmental abnormalities have been observed in birds in 2013, although significant genetic damage has not yet been documented for birds or rodents.

DTRA Chief: “We provided safe and secure storage for deadly pathogens in former USSR countries” 2009

Do I need to spell it out?
They are using these grounds for experiments.
Did they end up being experiment grounds by accident?
People in Chernobyl have been evacuated, but fauna and flora are hardly impacted by radiation.
Radiation does not discriminate by species.
You know who does that?
Viruses and bacteria.

DTRA 2008: “We design and test weapon systems and pathogens”
Notice anything interesting in this 2018 DTRA presentation?

DARPA IS A PENTAGON AGENCY WOKING FOR AGRICULTURE WITH GENETICALLY MODIFIED INSECTS THAT CAN POTENTIALLY BE WEAPONIZED. THEY SAY.

DARPA Presents Its “Insect Allies” Genetic Modification Program “for Agriculture”
“DARPA’s GMO insects program can be weaponized” – US scientists sounded the alarm years ago

WASHINGTON — DARPA, the Pentagon’s high-tech office, is working with the government of Ukraine to develop capabilities to help Kiev in its hybrid warfare challenge.

DARPA director Steven Walker, who recently took over that job after five years as the agency’s deputy, told reporters that he had personally visited the country in 2016 for talks with Ukrainian military, intel and industry leaders.

“We did have a good visit to the Ukraine,” Walker said Thursday at a breakfast hosted by the Defense Writer’s Group. “Yes, we have followed up with them, and through the U.S. European Command, we have started several projects with the Ukraine, mostly in the information space.”

“Not providing them weapons or anything like that, but looking at how to help them with information,” Walker added, before declining to go into further detail.

Ukraine has become a testing ground for hybrid warfare techniques from Russia and Russian-backed militant groups ever Russia’s invasion of Ukrainian territory in 2014, including disinformation campaigns. While that has allowed Moscow to test out new capabilities and techniques, it also provides an opportunity to develop counter techniques — which may benefit the U.S. and its allies in the long term.

“I think we’ve got to get better, as a country, in information warfare and how we approach info warfare,” Walker said. “I think there are capabilities there that we need to improve upon, and DAPRA is working in some of those areas.”

This is not the first tie between DARPA and Kiev. The Ukrainian government has hired Tony Tether, who led DARPA for the entirety of the George. W. Bush administration, to help lead a reorganization of their science and technology efforts, something Tether in a LinkedIn post said was necessary in part because so much of Ukraine’s S&T facilities were in the territory seized by Russia.

The former DARPA head has also consulted for the Ukroboronprom group, Ukraine’s largest defense contractor, and just a few weeks ago was added to the group’s supervisory board in a move that Ukrainian president Petro Poroshenko called a “symbol of effective cooperation between Ukrainian and American partners.”

Tether is expected to try and recreate some of what make DARPA so successful in Ukraine, but Walker notes that many countries have tried to do that — and failed, in large part due to a cultural fear of giving workers the freedom to fail they need.

“When I talk to others about DARPA and why it works, many other cultures say ‘this couldn’t happen,’” Walker noted.

More broadly, Walker said part of what he wants to see at DARPA during his tenure is looking at increasing counterinsurgency capabilities.

“I think as more populations across the world move to larger and larger cities, we need to understand the three dimensionality of cites and how to operate in those very crowded, very three-dimensional spaces,” Walker said, noting DARPA is working on ways to sense and map underground tunnels and infrastructure.

Updated 3/1/18 at 1:45 PM EST to reflect the fact that after publication, DARPA confirmed that Walker visited Ukraine in 2016.

About Aaron Mehta

Aaron Mehta was deputy editor and senior Pentagon correspondent for Defense News, covering policy, strategy and acquisition at the highest levels of the Defense Department and its international partners.

DARPA Is Making Insects That Can Deliver Bioweapons, Scientists Claim

BY HANNAH OSBORNE ON 10/4/18 AT 2:00 PM EDT

gettyimages-139677923
The U.S. government’s Defense Advanced Research Projects Agency (DARPA) has been accused of trying to create a new class of biological weapons that would be delivered via virus-infected insects. Aphids are one of the insects being used in the DARPA program.ISTOCK

The U.S. government’s Defense Advanced Research Projects Agency (DARPA) has been accused of trying to create a new class of biological weapons that would be delivered via virus-infected insects.

The Insect Allies program was announced by DARPA in 2016. It is a research project that aims to protect the U.S. agricultural food supply by delivering protective genes to plants via insects, which are responsible for the transmission of most plant viruses. Scientists believe loading the bugs up with viruses that would offer plants protective benefits could be one way of ensuring food security in the event of a major threat.

In an editorial published in the journal Science, a group of researchers led by Richard Guy Reeves, from the Max Planck Institute for Evolutionary Biology in Germany, says Insect Allies isn’t exactly what it says it is. Instead, they claim DARPA is potentially developing insects as a means of delivering a “new class of biological weapon.”

How Does Insect Allies Work?

There are many threats that could impact upon food security. This includes environmental disasters, natural pathogens and intentional attacks. Crop failure, for whichever of these reasons, has the potential to have devastating consequences—wheat and maize, for example, are relied upon by hundreds of millions across the globe for their basic nutritional needs.

ConceptArtInsectAlliesOctober32016v4FINAL619-316
Scientists with the Defense Advanced Research Projects Agency (DARPA) are looking at introducing genetically modified viruses that can edit chromosomes directly, like using insects to transmit genetically modified material into plants.DARPA

Genetically altering a species to make it more resilient comes with problems. Introducing alterations directly into a species’ chromosome is slow, as the alteration must be passed down through generations before it takes hold.

Instead, scientists with DARPA are looking at introducing genetically modified viruses that can edit chromosomes directly in fields—these are known as horizontal environmental genetic alteration agents (HEGAAs).

The DARPA program is using the principles of HEGAAs but, unlike traditional methods of dispersal—like spraying fields with them—it wants to spread them through insects. At the moment, maize and tomato plants are being used in experiments and the insects being used for dispersal are leafhoppers, aphids and whiteflies.

“Insect Allies aims to develop scalable, readily deployable, and generalizable countermeasures against potential natural and engineered threats to mature crops,” Blake Bextine, DARPA Program Manager for Insect Allies, told Newsweek. “The program is devising technologies to engineer and deliver these targeted therapies on relevant timescales—that is, within a single growing season. To do so, Insect Allies researchers are building on natural, efficient, and highly specific plant virus and insect vector delivery systems to transfer modified, protective genes to plants.”

Why Biological Weapons?

Reeves and his colleagues offer a number of assertions about why Insect Allies could end up being a means of bioweapon dispersal. Firstly, they question the very nature of the project—the use of insects. Why, they say, are insects so integral? What is the problem with spraying HEGAAs?

The team says Insect Allies “appears very limited in its capacity to enhance U.S. agriculture or respond to national emergencies…. As a result, the program may be widely perceived as an effort to develop biological agents for hostile purposes and their means of delivery.”

Potentially, the viruses being introduced could do harm instead of good. The insects could be used to disperse agents that would prevent seeds from growing. “HEGAA weapons could be extremely transmissible to susceptible crop species, particularly where insects were used as the means of delivery,” they write. “Chromosomal editing would be targetable to particular crop varieties dependent on their genome sequence (presumably those varieties not grown by the deploying parties).”

gettyimages-935444786
Maize, one of the crops being tested by Defense Advanced Research Projects Agency (DARPA), is relied upon by millions of people for basic nutrition. Scientists believe loading the bugs up with viruses that would offer plants protective benefits could be one way of ensuring food security in the event of a major threat.ISTOCK

The development of an insect-based system, according to the authors, points to “an intention to develop a means of delivery of HEGAAs for offensive purposes.” The technology, they say, could quickly be simplified and used to develop a whole new class of biological weapons. “In our view, the program is primarily a bad idea because obvious simplifications of the work plan with already-existing technology can generate predictable and fast-acting weapons, along with their means of delivery, capable of threatening virtually any crop species,” they wrote.

The team calls for more transparency from DARPA as the Insect Allies progresses. However, it also says the potential to weaponize this technology is already out there. They say weapons programs are driven by the perceived activities of competitors—maybe the Insect Allies program is a response to intelligence about another nation’s capabilities.

Furthermore, “the mere announcement of the Insect Allies Program, with its presented justifications, may motivate other countries to develop their own capabilities in this arena—indeed, it may have already done so…. Reversal of funding for this DARPA project…would not in itself close the particular Pandora’s box that HEGAAs or their insect dispersal may represent.”

RELATED STORIES

DARPA Making Weaponized Insects?

DARPA denies the assertions made by Reeves and his colleagues. “DARPA is producing neither biological weapons nor the means for their delivery,” a spokesman told Newsweek. “We do accept and agree with concerns about potential dual use of technology, an issue that comes up with virtually every new powerful technology.” He said these concerns are the reason Insect Allies has been structured in the way it is—supposedly as a transparent and university-led research project that encourages communication. “We also have numerous, layered safeguards in place to maintain biosecurity and ensure the systems we’re developing function only as intended,” the DARPA spokesperson added.

Bextine reiterated this point. Researchers working with DARPA are allowed to publish their results and work with different agencies. The experiments they carry out are done so in biosecure greenhouses. “At no point in the program is DARPA funding open release of Insect Allies systems,” Bextine said.

He said he disagrees with the conclusion of the editorial in Science, saying technology and research that deals with food security and gene editing “have a higher bar than most for transparency”—and Insect Allies, he says, meets these high standards.

Responding to the queries relating to delivery—why spraying technology cannot be used—Bextine said these are just not up to the challenge, especially when it comes to responding at a large scale to the most severe threats.

“Many existing methods for protecting crops are inefficient, expensive, imprecise, or destructive to plants, may require significant infrastructure, and often provide only limited efficacy,” he said. “Sprayed treatments are impractical for introducing genetic modifications on a large scale and potentially infeasible if the spraying technology does not access the necessary tissues with specificity. Meanwhile, traditional selective breeding methods for introducing protective traits into plants require years to propagate, nowhere near the speed required to prevent a fast-moving threat from developing into a crisis.”

He added that DARPA would never receive funding for the next generation of aerial spraying technology. The development of this new technology is dependent on industry and other research funders. “Instead, we reach for fundamentally new ways of delivering more precise, efficacious treatments through systems that can be readily adapted to confront a range of potential threats.

“Emerging biotechnologies—and especially the cutting-edge research being performed on Insect Allies—are pushing science into new territories. DARPA is proud to be taking a proactive role in working with stakeholders to inform a new framework for considering how the benefits of these technologies can be most safely realized.”

US military plan to spread viruses using insects could create ‘new class of biological weapon’, scientists warn

Agency says it is trying to genetically modify crops, but experts think this goal is ‘simply not plausible’

The Independent, 05 October 2018 11:16

US military plan to spread viruses using insects could create ‘new class of biological weapon’, scientists warn

Insects could be turned into “a new class of biological weapon” using new US military plans, experts have warned.

The Insect Allies programme aims to use bugs to disperse genetically modified (GM) viruses to crops.

Such action will have profound consequences and could pose a major threat to global biosecurity, according to a team that includes specialist scientists and lawyers.

However, the Defence Advanced Research Projects Agency (Darpa), which is responsible for developing military technologies in the US, says it is merely trying to alter crops growing in fields by using viruses to transmit genetic changes to plants.

In theory, this rapid engineering would allow farmers to adapt to changing conditions, for example by inserting drought-resistance genes into corn instead of planting pre-engineered seeds.

But this seemingly inoffensive goal has been slammed by the scientists, who say the plan is simply dangerous and that insects loaded with synthetic viruses will be difficult to control.

They also say that despite being in operation since 2016 and distributing $27m in funds to scientists, Darpa has failed to properly justify the existence of such a programme.

Research programme with potential for dual use: scientists fear that the Insect Ally programme by the US could encourage other states to increase their own research activities in the field of biological warfare (MPG/D.Duneka)
Research programme with potential for dual use: scientists fear that the Insect Ally programme by the US could encourage other states to increase their own research activities in the field of biological warfare (MPG/D.Duneka) (MPG/ D. Duneka)

“Given that Darpa is a military agency, we find it surprising that the obvious and concerning dual-use aspects of this research have received so little attention,” Felix Beck, a lawyer at the University of Freiburg, told The Independent.

Dr Guy Reeves, an expert in GM insects at the Max Planck Institute for Evolutionary Biology, said that there has been hardly any debate about the technology and the programme remains largely unknown “even in expert circles”.

He added that despite the stated aims of the programme, it would be far more straightforward using the technology as a biological weapon than for the routine agricultural use suggested by Darpa.

“It is very much easier to kill or sterilise a plant using gene editing than it is to make it herbicide or insect-resistant,” explains Reeves.

Experiments are reportedly already underway using insects such as aphids and whiteflies to treat corn and tomato plants.

Mr Beck said he and fellow experts were not suggesting that the US military wanted to create biological weapons, but that the proposed agricultural uses are “simply not plausible for a number of reasons”.

Firstly, they note that if farmers wanted to use genetically modified viruses to improve their crops, there is no reason not to use conventional spraying equipment.

They also noted that despite Darpa stating that no insects used should survive longer than two weeks, if such safeguards were not in place “the spread could in principle be unlimited”.

Mr Beck added: “The quite obvious question of whether the viruses selected for development should or should not be capable of plant-to-plant transmission – and plant-to-insect-to-plant transmission – was not addressed in the Darpa work plan at all”.

Air Force fails to acknowledge mysterious meteor that crashed to Earth near US military base

Making their case in the journal Science, the team noted that if Insect Allies’ research cannot be justified, it could be perceived as breaching the UN’s Biological Weapons Convention.

“Because of the broad ban of the Biological Weapons Convention, any biological research of concern must be plausibly justified as serving peaceful purposes,” explained Professor Silja Voeneky, a specialist in international law at Freiburg University.

“The Insect Allies Program could be seen to violate the Biological Weapons Convention, if the motivations presented by Darpa are not plausible.

“This is particularly true considering this kind of technology could easily be used for biological warfare.”

To prevent any suspicion and to avoid encouraging other nations to develop their own technologies in this area, the authors of the study have called for more transparency from Darpa if it intends to pursue such programmes.

A spokesperson from Darpa defended the programme, explaining that using insects to apply these gene altering treatments could provide advantages over sprays.

“Most importantly in this context, sprayed treatments are impractical for introducing protective traits on a large scale and potentially infeasible if the spraying technology cannot access the necessary plant tissues with specificity, which is a known problem,” they said.

“If Insect Allies succeeds, it will offer a highly specific, efficient, safe, and readily deployed means of introducing transient protective traits into only the plants intended, with minimal infrastructure required.”

LMFAO

Ukroboronprom Appoints Former DARPA Head as Supervisory Board Member

Ukroboronprom Appoints Former DARPA Head as Supervisory Board Member

Anthony Tether, Former Head of US DARPA was appointed as member of UOP Supervisory Board (Image: Ukroboronprom)

Ukraine’s state run Ukroboronprom has appointed former head of US Defense Advanced Research Projects Agency (DARPA), Anthony Tether as member of UOP Supervisory Board.

Anthony Tether has been in charge of Ukroboronprom long-term development for over a year and a half. He assists in implementing UOP development strategy, implementation of reforms, corporatization, and international audit. The former head of DARPA contributed to strengthening Ukroboronprom’s export potential and investment development. Under his chairmanship, the State General Advanced Research and Development Agency (GARDA, the prototype of the American DARPA) was created, the company said in a statement Thursday.

“As a member of the Supervisory Board, Anthony Tether will help Ukroboronprom to implement the reform strategy and international audit,” said Roman Romanov, Ukroboronprom Director General.

Earlier, Mykhaylo Zhurovs’kyy – the rector of the National Technical University of Ukraine “Kyiv Polytechnic Institute named after I. Sikorsky” – was elected as Chairman of the Supervisory Board. Lieutenant General Yaroslav Skal’ko, former commander-in-chief of the Ukrainian Air Force, was elected as Vice-Chairman.

On January 31, the Ukroboronprom Supervisory Board – after a long-term meeting -took key decisions on the activities of the Concern. During the meeting, UOP management report was heard; strategic directions for UOP development, corporatization process of UOP enterprises-participants, the international audit, the system of effective anti-corruption measures, creation of an advisory body and other issues were discussed.

Ukraine to Create DARPA-like Defence Research Agency

Ukraine to Create DARPA-like Defence Research Agency

Ukriane will soon set up its General Advanced Research & Development Agency (GARDA), modeled along the American Defence Advanced Research Projects Agency (DARPA) at Igor the Sikorsky Kyiv Polytechnic Institute (KPI).

This was stated by UKROBORONPROM Director General Pavlo Bukin during his speech at the Verkhovna Rada of Ukraine, during the parliamentary hearings “National Innovation System: State and Legislative Development”.

“It was decided to create an agency of advanced technologies based on the DARPA model, to implement technologies in the defense industry. Mykhaylo Zhurovs’kyy – the rector of the National Technical University of Ukraine “Kyiv Polytechnic Institute named after I. Sikorsky” – agreed that the agency will be based at this very university. I am sure this decision will contribute to the greatest effect”, stressed Pavlo Bukin.

At the same time, he mentioned that the issue of innovative technologies development is connected with the necessity of legislative changes that would improve the mechanisms of financing such projects.

“The legal framework for innovation in Ukraine is sufficiently developed, but some aspects need to be improved, as they hamper financing. When it comes to research institutes and design bureaus – their resources are limited. It is necessary to legislatively create a mechanism for innovation activity financing and preferential taxation, “- said UKROBORONPROM Director General Pavlo Bukin from the rostrum of the Verkhovna Rada of Ukraine.

He named UGV “Phantom-2” development among UOP innovations. “This platform allows to destroy the enemy’s manpower and to transport the goods, and it has already passed the test abroad, and it can be considered to be a result of the activities of the State Concern and its design engineering bureaus,” said Pavlo Bukin.

Ukroboronprom head: Ukraine’s military industrial complex during hybrid warfare

By Roman Romanov, Dec 11, 2017
Roman Romanov is the director general of Ukrainian defense company Ukroboronprom.

Three years ago, Ukraine was facing an unexpected challenge – Russia’s military aggression. The annexation of Crimea and the first battles in Donbass were a total shock to the Ukrainian armed forces and the domestic defense industry. At that time, defense and law enforcement agencies were uncapable of performing their tasks; weapons and military equipment were not ready for operational use; and the military-industrial complex could not meet the needs of the Army.

Unfortunately, over the past 25 years, Ukrainian defense enterprises received no orders from the state – more than half of the plants were practically closed. The main types of the military equipment manufactured required Russian components.

Outlook 2018: Perspectives from global thought leaders

In 2014, we completely stopped our cooperation with the Russian defense industry, and Ukroboronprom received the task to provide the Army with necessary weapons and military equipment in the shortest possible time.

First of all, we formed a new team of Ukroboronprom managers, who managed to quickly make qualitative changes and introduce the best business and management practices. We replaced about half of the directors of Ukroboronprom enterprises, mainly those who failed to adapt their way of thinking to new realities; we initiated repair and overhaul of the military equipment – Ukroboronprom enterprises organized 55 mobile maintenance crews, restoring military equipment directly in the anti-terrorist operation zone.

Furthermore, we arranged the import of critical components and organized the repair and manufacture of modernized military equipment samples. Ukroboronprom heads for strategic partnership with Western countries and NATO-Ukraine defense-technical cooperation.

In 2015, Ukroboronprom began implementing a new strategic task – the State Defense Order. Ukroboronprom enterprises launched serial production of new military equipment samples. The Army began to receive sniper rifles, mortars, modernized tanks and new armored personnel carriers manufactured in Ukraine.

The next urgent task was set: to overcome the dependence on imported components from the Russian Federation. To solve this problem, we launched a large-scale import substitution program to attract domestic reserves and set up cooperation within the country with enterprises of any form of ownership.

Ukroboronprom representatives visited all regions of Ukraine, held meetings with governors and discussed the issues of attracting the region’s industry to cooperation with Ukroboronprom.

As a result, enterprises from all regions of Ukraine began to join the import-substitution program implementation. As of today, 414 small, medium and large enterprises of Ukraine and 200,000 specialists joined the process. In fact, Ukroboronprom has attracted the whole country to working on strengthening the Ukrainian Army and the development of the country’s economy.

Furthermore, we renewed the workforce, attracted scientific and educational potential of the country: memorandums of cooperation were signed with 48 Ukrainian universities. Today, we train young specialists: 8,000-plus students had their practical training at Ukroboronprom enterprises and almost 600 of them are already working at our plants.

Memorandums of cooperation were signed with 30 institutes of the National Academy of Sciences of Ukraine. Attracting talented Ukrainian scientists and young specialists resulted in 535 promising developments upon the anvil and 80 projects that are already being implemented at Ukroboronprom enterprises.

We set ourselves to the task of expanding partnerships and implementing NATO standards for all stages of armament life cycles. The work on the introduction of the AQAP 2000 series standards at Ukroboronprom enterprises is launched. The ISO 9001 system already operates at 73 percent for Ukroboronprom enterprises.

Ukroboronprom specialists actively participate in multinational projects of the NATO concept Smart Defence, as well as in the meetings of the NATO-Ukraine Joint Working Group on Defence-Technical Cooperation.

In 2016, the development of the Ukroboronprom reform strategy was launched. The state concern Ukroboronprom held a meeting of a specially established tendering committee, involving the specialist of the Independent Defence Anti-Corruption Committee of Transparency International Ukraine, to help select the international consulting company using a “competitive dialogue” procedure. Thus, the concern started the process of conducting an international audit. We launched the next stage of Ukroboronprom’s reform. Implementation of such a large-scale process – as international audit and transformation of Ukroboronprom’s enterprises into joint stock companies – will last for about two years.

As a result of military operations in the anti-terrorist operation area, 900-plus technical solutions were introduced and implemented by Ukroboronprom engineers in the armored vehicles operated by the Army, having significantly improved tactical and operational characteristics of the military equipment and taking into account hybrid war experience.

Today, the latest developments of our specialists are being used and tested in the anti-terrorist operation zone. A good example is the unmanned complex Spectator, developed by the specialists of state concern Ukroboronprom, together with scientists of the National Technical University of Ukraine “Igor Sikorsky Kyiv Polytechnic Institute.” In May 2015, a contract for production was signed. And in January 2016, the first batch was transferred to Ukraine’s armed forces. This high-tech product has been successfully used in combat conditions for more than a year. The prototype of the new tactical UAV, Horlytsya, developed by the Ukrainian enterprises, successfully performed its first flight.

Hybrid war in the east of Ukraine forced us – taking into account combat experience – to develop unmanned equipment for performing various tasks on the battlefield without putting our soldiers’ lives at risk.

Ukroboronprom withstood the challenge of the war and in three years transferred about 16,000 units of weapons and military equipment to the military. Thanks to the work of the entire defense industry of Ukraine, our armed forces – from combat-ineffective units in 2014 – turned into a well-armed Army.

DARPA wants to alter human skin biomes to fight deadliest enemy: mosquitos

Researchers developing long-lasting topical cream that alters skin’s “microbiome” so troops can ward off disease-carrying insects.

Breaking Defense, March 07, 2022

Mosquitos potentially carry a range of deadly diseases, from malaria to yellow fever. (Photo by James Gathany/CDC. Public Domain.)

WASHINGTON: The Defense Advanced Research Projects Agency may have been created to develop cutting-edge technology to help the US take on the Soviet Union in the Cold War, but now it’s taking on another deadly enemy: mosquitos.

DARPA’s latest idea, now entering its second phase, is to get down to the molecular level to make a topical cream that would actually alter the “microbiome” of human skin to make it less appetizing to the disease-carrying insects.

“The ReVector program aims to precisely, safely, and efficiently reduce mosquito attraction and biting, and, subsequently, to help maintain the health of military personnel operating in disease-endemic regions,” the agency said in a release last month.

While tiny compared to the USSR and totally lacking artillery, the mosquito is the deadliest animal on the planet, responsible for spreading malaria, which kills more than 400,000 people every year, in addition to other deadly diseases. Throughout human history militaries have struggled with mosquito-borne maladies, from the million-plus cases that waylayed soldiers during the Civil War to the over 80,000 cases among US servicemembers in Vietnam.

Even though a vast majority of those survived, the disease disrupted the forces’ ability to fight, at times in critical moments. Army researchers currently estimate malaria infections are responsible for up to 21,000 lost work hours and between $1.2 and $4.4 million per year in evacuation and medical costs.

The treatment for malaria has progressed significantly in recent decades, but the ReVector program aims to stop the disease before it can get into the human body at all. The program’s first phase involved the development of technology to “modify human skin microbes” and the “volatile molecules” it produces, and testing the effect of those modifications on mosquitos.

“In Phase 2, the team plans to advance testing in animal models and move complex microbiome communities,” ReVector program manager Linda Chrisley said in the release.

The release explained that “ultimately, ReVector seeks to develop topical formulations that could be applied shortly before a mission with minimal equipment or training, and last for at least two weeks without reapplication, offering improved, sustained protection against disease vectors.”

DARPA is working with Stanford University researchers on the project, and the agency notes the research is reviewed by the US Food and Drug Administration and “if necessary” the Environmental Protection Agency “to ensure that technologies are effective and do not pose a threat to humans or the environment.”

PENTAGON UNIT A1266 STUDIES INSECTS AS BIOTERRORISM AGENTS ON RUSSIA’S DOORSTEPS:

Pentagon Biolabs – Russia has been long complaining about them – 2018 Investigative Documentary

Entomological Warfare?

DARPA has been working for several years on genetic editing of mosquitoes. Through its “Insect Allies” program, DARPA has been working, using CRISPR gene-editing and gene drive technologies, on manipulating the Aedes Aegypti mosquito. The US Department of Defense has spent at least $100 million in the controversial technology known as “gene drives” making the US military a top funder and developer of the gene-modifying technology. “Gene drives are a powerful and dangerous new technology and potential biological weapons could have disastrous impacts on peace, food security and the environment, especially if misused,” said Jim Thomas, co-director of ETC Group, an environment safety group. “The fact that gene drive development is now being primarily funded and structured by the US military raises alarming questions about this entire field.”

Entomological warfare is a type of biological warfare that uses insects to transmit diseases. The Pentagon, using DARPA research, has allegedly performed such entomological tests secretly in the Republic of Georgia and Russia. Is the DARPA development, together with Gates’ foundation and Oxitec, of the gene edited mosquitoes a covert program in entomological warfare?

The Pentagon presently has top security bio laboratories in 25 countries across the world funded by the Defense Threat Reduction Agency (DTRA) under a $ 2.1 billion military program– Cooperative Biological Engagement Program (CBEP). They are in former Soviet Union countries such as Georgia and Ukraine, the Middle East, South East Asia and Africa. Among their projects, Phlebotomine sand fly species were collected under the heading, “Surveillance Work on Acute Febrile Illness,” in which all (female) sand flies were tested to determine their infectivity rate. A third project, also including sand flies collection, studied the characteristics of their salivary glands. This is weaponization research.

The controversial person picked by the Biden Administration to become the first Cabinet-level science advisor, Eric Lander, came from the MIT-Harvard Broad Institute. Lander is a specialist in gene drive and gene editing technologies and played a major role in the flawed US Human Genome Project. This is not the kind of science we need to be supporting. It is rather part of what is obviously a larger eugenics agenda and Bill Gates is again playing a key role.
SOURCE

BONUS:

US military to develop genetically modified plants to use as spies

New synthetic biology programme makes use of natural capabilities to gather intelligence

The Independent, 23 November 2017 16:55

The highly attuned sensory abilities of plants could be employed to gather intelligence for the military
The highly attuned sensory abilities of plants could be employed to gather intelligence for the military (Getty Images/iStockphoto)

The US military wants to deploy plants as “the next generation of intelligence gatherers”.

Genetically modified plants could be employed as self-sustaining sensors to gather information in settings unsuitable for more traditional technologies.

The Defence Advanced Research Projects Agency (DARPA), which is responsible for the development of emerging technologies in the US military, has called for scientists to submit ideas for how to harness the power of plants.

In the past, DARPA has produced information-gathering technologies such as the satellites and seismographs employed to ensure Soviet compliance with the Nuclear Test Ban Treaty.

But in this new initiative, termed the Advanced Plant Technologies (APT) programme, the agency is looking to the natural world for help.

“Plants are highly attuned to their environments and naturally manifest physiological responses to basic stimuli such as light and temperature, but also in some cases to touch, chemicals, pests and pathogens,” said Dr Blake Bextine, the manager of the ATP programme.

“Emerging molecular and modelling techniques may make it possible to reprogramme these detection and reporting capabilities for a wide range of stimuli, which would not only open up new intelligence streams, but also reduce the personnel risks and costs associated with traditional sensors,” said Dr Bextine.

The idea is that plants’ natural capabilities can be co-opted to detect relevant chemicals, harmful microorganisms, radiation and electromagnetic signals.

Modifying the genomes of plants would enable the military to control the types of sensing they are doing, and also trigger certain responses that can be monitored remotely using existing hardware.

Technology already exists to monitor plants from the ground, air and even from space.

“Advanced Plant Technologies is a synthetic biology programme at heart,” said Dr Bextine.

“As with DARPA’s other work in that space, our goal is to develop an efficient, iterative system for designing, building, and testing models so that we end up with a readily adaptable platform capability that can be applied to a wide range of scenarios.”

Past experiments with plants that have been modified in this manner have resulted in organisms that have difficulty settling in the natural environment, where they would be deployed.

The additional strain placed on the modified plants by their new duties makes it difficult for them to survive and compete with surrounding plants. This will be a key area that the new programme seeks to address.

The “proposers day” is being held on 12 December in Arlington, Virginia. It will lay out the objectives of DARPA’s programme and take submissions for research projects that are relevant to the initiative.

Gene Edited Catastrophe in Brazil

New Eastern Outlook, 02.10.2019 Author: F. William Engdahl

A British-American gene-editing company has released millions of genetically modified mosquitoes containing a dominant lethal gene, each week for 27 months in the Bahia, Brazil region in a test to see if the gene-edited mosquitoes would mate with local mosquitoes carrying Zika, malaria or other mosquito-borne diseases. A new study documents the alarming fact that following an initial reduction of the target population of mosquitoes, after some months the “population which had been greatly suppressed rebounded to nearly pre-release levels.” Scientists to date have no idea what dangers are presented by the new mutations. This once more highlights the dangers of uncontrolled gene-editing of species.

According to a new published study in Nature Reports journal, genetically engineered mosquitoes produced by the biotech company, Oxitec, now part of the US company Intrexon, have escaped human control after trials in Brazil and are now spreading in the environment.

On paper the theory was brilliant. Strains of “yellow fever” male mosquitoes taken from Cuba and Mexico were altered using gene-editing to make it impossible for their offspring to survive. Oxitec then began a systematic release of tens of millions of the manipulated mosquitoes over more than two years in the the city of Jacobina in the region of Bahia in Brazil. The Oxitec theory was the altered mosquitoes would mate with normal females of the same type which carry infectious diseases like dengue fever, and kill them off in the process.

Unanticipated Outcome…’

A team of scientists from Yale University and several scientific institutes in Brazil monitored the progress of the experiment. What they found is alarming in the extreme. After an initial period in which the target mosquito population markedly declined, after about 18 months the mosquito population recovered to pre-release levels. Not only that, the paper notes that some of the mosquitos likely have “hybrid vigor,” in which a hybrid of the natural with the gene-edited has created “a more robust population than the pre-release population” which may be more resistant to insecticides, in short, resistant “super mosquitoes.”

The scientists note that, “Genetic sampling from the target population six, 12, and 27–30 months after releases commenced provides clear evidence that portions of the transgenic strain genome have been incorporated into the target population. Evidently, rare viable hybrid offspring between the release strain and the Jacobina population are sufficiently robust to be able to reproduce in nature…” They continue, “Thus, Jacobina Ae. aegypti are now a mix of three populations. It is unclear how this may affect disease transmission or affect other efforts to control these dangerous vectors.” They estimate that between 10% and 60% of the Bahia natural Ae. Aegypti mosquitoes now had some gene-edited OX513A genome. They conclude that “The three populations forming the tri-hybrid population now in Jacobina (Cuba/Mexico/Brazil) are genetically quite distinct, very likely resulting in a more robust population than the pre-release population due to hybrid vigor.”

This was not supposed to happen. Professor of ecology and evolutionary biology, Jeffrey Powell, senior author of the study, remarked on the findings: “The claim was that genes from the release strain would not get into the general population because offspring would die. That obviously was not what happened.” Powell went on to note, “But it is the unanticipated outcome that is concerning.”

A Gates Foundation Project

The Brazil study deals a major alarm signal on the uncontrolled release of gene-edited species into nature. It calls to mind the horror plot of Michael Crichton’s 1969 science fiction novel, Andromeda Strain. Only it is no novel.

The Oxitec mosquitoes were developed using a highly controversial form of gene-editing known as gene drive. Gene Drive, which is also being heavily funded by the Pentagon’s DARPA, combined with CRISPR gene-editing, aims to force a genetic modification to spread through an entire population, whether of mosquitoes or potentially humans, in just a few generations.

The scientist who first suggested developing gene drives in gene-editing, Harvard biologist Kevin Esvelt, has publicly warned that development of gene editing in conjunction with gene drive technologies has alarming potential to go awry. He notes how often CRISPR messes up and the likelihood of protective mutations arising, making even benign gene drives aggressive. He stresses, “Just a few engineered organisms could irrevocably alter an ecosystem.” Esvelt’s computer gene drive simulations calculated that a resulting edited gene “can spread to 99 percent of a population in as few as 10 generations, and persist for more than 200 generations.” This is very much what has now been demonstrated in the mosquito experiment in Brazil.

Notable is the fact that the Oxitec Brazil mosquito experiment was funded by the Bill & Melinda Gates Foundation. In June, 2018 Oxitec announced a joint venture with the Gates Foundation, “to develop a new strain of Oxitec’s self-limiting Friendly™ Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere.” The Brazil results show the experiment is a catastrophic failure as the new strain is anything but self-limiting.

The Gates Foundation and Bill Gates have been backing development of the radical gene-editing technology and gene drive technology for more than a decade. Gates, a long-time advocate of eugenics, population control and of GMO, is a strong gene-editing promoter. In an article in the May/June 2018 magazine of the New York Council on Foreign Relations, Foreign Affairs, Gates hails gene editing technologies, explicitly CRISPR. In the article Gates argues that CRISPR and other gene-editing techniques should be used globally to meet growing demand for food and to improve disease prevention, particularly for malaria. In his article he adds, “there is reason to be optimistic that creating gene drives in malaria-spreading mosquitoes will not do much, if any, harm to the environment.

Every bit as alarming as the failure of the Brazil gene-editing mosquito experiment is the fact that this technology is being spread with virtually no prior health or safety testing by truly independent government institutions. To date the US Government relies only on industry safety assurances. The EU, while formally responsible to treat gene-edited species similarly to GMO plants, is reportedly trying to loosen the regulations. China, a major research center for gene-editing, has extremely lax controls. Recently a Chinese scientist announced an experiment in human gene-editing allegedly to make newborn twins resistant to HIV. Other experiments are proliferating around the world with gene-edited animals and even salmon. The precautionary principle has been thrown to the winds when it comes to the new gene-editing revolution, not a reassuring situation.

Currently Oxitec, which denies that the Brazil results show failure, is now trying to get regulatory approval from the US Environmental Protection Agency to conduct a similar experiment with the same gene-edited species in Texas and Florida. One of the people involved in the attempt, Texan Roy Bailey, is a Washington lobbyist and close friend of Randal Kirk, the billionaire CEO of Intrexon, owner of Oxitec. Bailey is also a major Trump fundraiser. Let’s hope that regulatory prudence and not politics decide the outcome

F. William Engdahl is strategic risk consultant and lecturer, he holds a degree in politics from Princeton University and is a best-selling author on oil and geopolitics, exclusively for the online magazine “New Eastern Outlook.”

MORE RESOURCES

Genetically modified mosquitoes could be released in Florida and Texas beginning this summer
https://theconversation.com/genetically-modified-mosquitoes-could-be-released-in-florida-and-texas-beginning-this-summer-silver-bullet-or-jumping-the-gun-139710

Gates Foundation Oxitec Grant
https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2018/06/OPP1181812

Gates Foundation and Oxitec Fight Malaria with Genetically-Modified Mosquitoes
https://www.labiotech.eu/industrial/gates-foundation-oxitec-malaria-mosquito/

Gates Foundation Awards $4.1 Million for Mosquito Engineering
https://philanthropynewsdigest.org/news/gates-foundation-awards-4.1-million-for-mosquito-engineering

Mosquitoes are the new syringe? Seattle lab nibbles at malaria vaccine
https://www.seattletimes.com/seattle-news/science/mosquitoes-are-the-new-syringe-seattle-lab-nibbles-at-malaria-vaccine/

Researchers Turn Mosquitoes Into Flying Vaccinators
https://www.sciencemag.org/news/2010/03/researchers-turn-mosquitoes-flying-vaccinators

US Army & Gates Study Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites (IMRAS)
https://clinicaltrials.gov/ct2/show/NCT01994525

Who is the biggest killer on the planet?
http://www.hardydiagnostics.com/wp-content/uploads/2016/05/The-Most-Deadly-Animals.pdf

EPA suspends enforcement of environmental laws amid coronavirus
https://thehill.com/policy/energy-environment/489753-epa-suspends-enforcement-of-environmental-laws-amid-coronavirus

So yeah, nothing to worry here, just “health labs” and SPAs …

Thanks Fukushima Exposed for the great and timely contribution that decisively helped me complete this investigation!

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

This might be the biggest news since Covid and, four days later, no one is talking about it. So big it’s worth sounding war drums to cover it.
Some scientists say it’s a 1/3trillion coincidence, others say it’s nothing amazing. I propose a my own solution to this debate.

The facts:

In a new study, published only four days ago in Frontiers in Virology, researchers compared the SARS-COV-2 makeup to millions of sequenced proteins in a database, finding a coincidence that they deem as a 1/3trillion mathematical probability.
The other element of the coincidence is the notorious Moderna 2016 invention patent for a technology included in a precursor to the Covid mRNA vaccine, the cancer mRNA jab they were working on at the time.

The virus is made up of 30,000 letters of genetic code that carry the information it needs to spread, known as nucleotides.

We’ve discussed this here (long course):

SCIENTIFIC CONSENSUS: WE’VE NEVER SEEN A VIRUS ISOLATE, JUST A MEMO FROM CHINA ON A SERVER

And here (dumbed down course)

WHY THE CHINA LAB LEAK IS JUST ANOTHER BLATANT PSY-OP REINFORCING THE MAIN LIE FOR UTTER MORONS, EXPLAINED TO CHILD-MINDED ADULTS WITH MANY COLORFUL ILLUSTRATIONS

Analysis of the original Covid genome found the virus shares a sequence of 19 specific letters with a genetic section owned by Moderna, which has a total of 3,300 nucleotides.

The few scientists that have reacted to this discovery so far haven’t denied it.
But some denied its importance and relevance, stating simplistically that 19 nucleotides out of 3300 is not much and can be a natural coincidence, possibly driven by common evolutionary needs. Except the patent is not the fruit of natural evolution, it wouldn’t be patentable if it were natural.

Daily Mail reports:

“Twelve of the shared letters make up the structure of Covid’s furin cleavage site, with the rest being a match with nucleotides on a nearby part of the genome. 
Writing in the paper, led by Dr Balamurali Ambati, from the University of Oregon, the researchers said the matching code may have originally been introduced to the Covid genome through infected human cells expressing the MSH3 gene.  
Professor Lawrence Young, a virologist at Warwick University, admitted the latest finding was interesting but claimed it was not significant enough to suggest lab manipulation. He told MailOnline:
‘We’re talking about a very, very, very small piece made up of 19 nucleotides. ‘So it doesn’t mean very much to be frank, if you do these types of searches you can always find matches. ‘Sometimes these things happen fortuitously, sometimes it’s the result of convergent evolution (when organisms evolve independently to have similar traits to adapt to their environment). ‘It’s a quirky observation but I wouldn’t call it a smoking gun because it’s too small. He added: ‘It doesn’t get us any further with the debate about whether Covid was engineered.’  
Dr Simon Clarke, a microbiologist at Reading University, questioned whether the find was as rare as the study claims. He told MailOnline:
‘There can only be a certain number of [genetic combinations within] furin cleavage sites. ‘They function like a lock and key in the cell, and the two only fit together in a limited number of combinations. ‘So it’s an interesting coincidence but this is surely entirely coincidental.’ 

Say what?!?!

“MailOnline has approached Moderna for comment.”

UDATE: Daily Mail couldn’t get a comment from Moderna, but Fox could. And it’s spectacular in its own very special way:

Moderna CEO scrambles to explain their 2016 invention patent containing SARS-Cov-2 elements

And I have reasons to think those guys suck balls and very likely this is the biggest news since Covid, hear me out:

This news is a perfect case study for a point I’ve been making for a long while: things in Universe exist in either of these three states:

  1. Natural occurrence beyond human influence aka COINCIDENCES

2. The aimed result of human deliberation and activity aka CONSPIRACIES.

3. A combination of 1. and 2. aka CONSPIRACIES GONE HAYWIRE, which I think describes 99% of human life experience.

And, based on history, lived or learned, pure coincidences are way more rare than pure conspiracies, or mixtures, so favoring coincidences over conspiracies is simply dumb and ignorant.

Thus,
Coincidence theorists are the ones who deserve the most scrutiny, mockery and ridicule.
In the human society, as opposed to nature, coincidence theories should be more seriously scrutinized than conspiracy theories.

It is crucial to find alternative ways to solve such a debate with means that are accessible to anyone that’s just a functional literate.

THE DISCUSSION

Is that nucleotide sequence a stunningly unlikely coincidence or just nothing special?

“One in three trillion” or “once in a while”?

How do we arbiter this high-expertise debate without having that expertise and without relying on pre-chewed opinions from dubious or biased experts?

I have a bachelor degree in journalism and public communication, and I’ve always been deeply interested in science even since before school. I have studied health (not just medicines) and physiology for my own understanding, use and benefit for over 20 years now. As a result, I haven’t used any medication in close to 15 years now. That’s where expertise ends for me. People with other occupations and passions need to be able to make their own minds on this because ‘expert’ nowadays is the politically correct term for whores.

I can’t calculate complicated probabilities, nor do I have the education and the practical experience of a virologist, as the majority of any media readership. But they don’t have my education either, and I bet you it’s just as useful.

So does this mean we can’t find a way to skin this cat and we have to take these conmen’s word?

Don’t be silly. This is SILVIEW.media

When it comes to chance and ‘probabilistics’, the most common reference is the lottery. Not so popular among the young ones, but I hope they have a grasp of it too. At least through some online games.

There are many models, I don’t play, I’ll just pick one that I remember from home.
It’s called “6 out of 49”. As the name suggest, from the numbers 1-49 they randomly pick 6 and you have to guess all of them. But they give you a decent prize even if you have five matches, because that’s extraordinary enough.


VERY IMPORTANTLY:
1. The order doesn’t matter.
2. The numbers don’t mean anything, they don’t have any function, nor do they make up a system.

There’s been years without any claim for the grand prize there. That’s how rare this coincidences are.

Now, in our dilemma we have a huge stream of only four characters, as the genome is made up of only four nucleobases: guanine, adenine, cytosine and thymine; in RNA, uracil is used in place of thymine.
They are symbolised with the letters A, C, G, T. Not by coincidence, they also form the name Gattaca.

So, in our genetic coincidence theory we have a stream of 3300 of these four elements and another one of 3000, and a fragment of 19 elements coincides between the two streams. Is that so amazing?

Maybe a superficial face value estimate, by the lottery model, “19 out of 3000” sounds insignificant, but that’s the wrong equation here.

Remember:
1. The order
2. The function

It’s not in the numbers, but in the succession and the function

As opposed to lottery, what surprises here is not that we have matching elements, but a massive matching sequence of elements.
That’s a whole new level of complexity.
We’re dealing with a mathematical combination of four elements taken 19 times. Now that mathematical function will yield a gigantic number of possibilities.

And then something takes things to a whole new level: the sequence is not just some random fragment from the character streams, it’s a full subsystem with its own functionality.

Twelve of the shared letters make up the structure of Covid’s furin cleavage site, with the rest being a match with nucleotides on a nearby part of the genome. 

And it’s not just any function, they are debating if this is what makes it more contagious, as in ‘the capabilities they add to viruses through gain-of-function research’!

According to Medical News Today:

  • Scientists do not yet fully understand how individual mutations in SARS-CoV-2 variants influence contagiousness or disease severity.
  • To enter a human cell, the SARS-CoV-2’s spike protein must be activated. This happens following cleavage by an enzyme called furin.
  • Scientists have theorized that mutations at the furin cleavage site might play an important role in a variant’s ability to infect or replicate in human cells.
  • Contrary to expectations, the authors of a new study found that this mutation did not influence the ability of the virus to enter or spread between cells.
  • Some variants of concern, such as Delta and Omicron, also have mutations at the same furin cleavage site, and this study may help understand the changes in their contagiousness and ability to produce disease.

More so, here’s a study titled ‘Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis’.

And guess what: The origin of SARS-CoV-2 furin cleavage site remains a mystery.

If it were a random coincidence, it wouldn’t have a meaning / function of its own, it would be… random.

How do you get from:

“Dr Simon Clarke, a microbiologist at Reading University, questioned whether the find was as rare as the study claims. He told MailOnline: ‘There can only be a certain number of [genetic combinations within] furin cleavage sites.
‘They function like a lock and key in the cell, and the two only fit together in a limited number of combinations. “

to:

“So it’s an interesting coincidence but this is surely entirely coincidental.” 

Daily Mail

Absolute non-sequitur. They literally demonstrated the opposite of their conclusion.
They simply count on you not critically analyzing things, just skimming headlines.

Because coincidence theorists are fucking dumb.

I mean, is it even theoretically possible if we factor in all the discussion above? What would be the likeliness? Sounds somewhere in the range of one in trillions to me. I’d personally round it up to an infinite.

While we can’t extract precise numbers with this method of reasoning, we can establish that this is the biggest lottery ticket ever won.

Disclaimer: this article does not imply that SARS-COV-2 exists in any other form and shape than a stream o characters on some computer hard drives. That’s all we’ve seen and analyzed here.

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER



It’s the best explanation for what we are witnessing, in my books, but watch my new video edit and make up your own mind.
And if he has attempted this, then the WEF has just shot one of its own kneecaps.

The Canadian Opportunity – Trudeau’s full speech at Davos 2016
“Justin is just a WEF mouthpiece” – Trudeau’s own half-brother
Trudeau’s half-brother sounds like his polar opposite, this sh!t is out of Lucas Films

BONUS: full LIST OF CANADIAN wef YOUNG GLOBAL LEADERS

Compiled from YGL’s own website:

Almost all of them…

The list only covers YGL in its current shape and form, from 2004 onwards. The community evolved on the shoulders of older Klaus Schwab projects that have continuity in YGL but aren’t covered here. Learn more here:
KLAUS SCHWAB’S YOUTH IS CALLED “YOUNG GLOBAL LEADERS”, READY FOR REGIME CHANGE IN UNALIGNED COUNTRIES

Chrystia Freeland

Deputy Prime Minister and Minister of Finance, Office of the Deputy Prime Minister of Canada, Canada

WEF profile

YGL profile

Sean Fraser

Ministry of Immigration, Refugees and Citizenship, Citizenship and Immigration Canada, Canada

François-Philippe Champagne

Minister of Innovation, Science and Industry, Innovation, Science and Economic Development Canada, Canada

Elissa Golberg

Assistant Deputy Minister for Strategic Policy, Global Affairs Canada, Canada

Karina Gould

Minister of Families, Children and Social Development, Employment and Social Development Canada, Canada

Renée Maria Tremblay

Senior Counsel, Supreme Court of Canada, Canada

Jagmeet Singh

Leader, Canada’s New Democrats, New Democratic Party of Canada, Canada

Kim Hallwood

Head of Corporate Sustainability, HSBC Bank Canada, Canada

Brett House

Deputy Chief Economist, Scotiabank, Canada

Catherine Raw

CHIEF OPERATING OFFICER, NORTH AMERICA, Barrick Gold Corporation, Canada

Jocelyn Formsma

Executive Director, National Association of Friendship Centres, Canada

Joelle Faulkner

President and Chief Executive Officer, Area One Farms, Canada

Ailish Campbell

Ambassador of Canada to the European Union, Global Affairs Canada, Canada

Jessica Burgner-Kahrs

Associate Professor, University of Toronto Mississauga, Canada

Scott Brison

Vice-Chair, Investment & Corporate Banking, BMO Financial Group, Canada

Tony Abrahams

Co-Founder and Chief Executive Officer, Ai-Media, Canada

Khaled Al Sabawi

Founder and Chief Executive Officer, Open Screenplay, Canada

Jennifer Corriero

Co-Founder and Executive Director, TakingITGlobal, Canada

Jean-François Gagné

VP AI, Canada

Nathaniel Harding

Managing Partner, Cortado Ventures, USA

Vera Kobalia

Co-Founder, Olyn, Canada

Michele Romanow

Co-Founder and President, Clear Finance Technology Inc – Clearbanc, Canada

Maya Roy

Chief Executive Officer, YWCA Canada, Canada

Liam Sobey

Vice-President, Merchandising, Sobeys Inc., Canada

Ilona Szabó de Carvalho

President, Igarape Institute, Canada

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

We warned you that giving these people free access to your body is a bad idea, for they will take advantage to put in and take out all sorts of things you don’t know about. Just like they do with everything else.

If you’ve been around for a while, this doesn’t really surprise you, but it’s a valuable confirmation and we can move over with this discussion.

If not, you definitely need to catch up with this too:

BGI – BILL GATES’ & BIG TECH’S CHINESE DARLINGS: WORLD’S TOP DNA HARVESTERS, CLONERS, UIGHUR PERSECUTERS (BIOHACKING P.4)

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

The Internets got agitated recently at the news that Moderna’s CEO, Stephane Bancel, dumped $400Million in Moderna stocks and nuked his Twitter account. Here’s why this shouldn’t surprise you and you should expect the worst any moment now.

Developing story, to be updated

Have you watched the former Blackrock director that went on Bannon’s War Room and prophesied that the Covid vaccines are a bubble that’s about to pop? Everything I’ve learned lately stands to support his claim.

This is him on Twitter:

If the dumping were a sudden and unusual move, this would indicate a recent event that shook the system, possibly rats leaving a sinking ship, a near threat for the business, as in:

That’s the case only partly, due to the stock crash overlapped with the incoming financial report, but a constant behavior over the span of months and years rather indicate a strategy and it’s associated with insider trading more often than not.

Surprisingly, it’s NPR of all the fakestream media who came in support of my suspicions, with a pretty merciless analysis of Moderna’s leadership financial behavior. And you know what’s funny? The piece dates all the way back to September 2020. I recommend reading the whole piece, I added the bolding and highlights :

Whether the coronavirus vaccine developed by Moderna succeeds or not, executives at the small biotech company have already made tens of millions of dollars by cashing in their stock. An NPR examination of official company disclosures has revealed additional irregularities and potential warning signs.

“On a scale of one to 10, one being less concerned and 10 being the most concerned,” said Daniel Taylor, an associate professor of accounting at the Wharton School, “this is an 11.”

Taylor said Moderna’s stock-selling practices appear well outside the norm, and raise questions about the company’s internal controls to prevent insider trading.

Since January, CEO Stéphane Bancel has sold roughly $40 million worth of Moderna stock held by himself or associated investment funds; Chief Medical Officer Tal Zaks has sold around $60 million; and President Stephen Hoge has sold more than $10 million.

Stéphane Bancel, chief executive officer of Moderna, has sold roughly $40 million worth of stock in the company since the beginning of this year.

The stock sales first came to widespread notice after Moderna announced positive early data from a vaccine trial in May [2020 – S.m.]. At that point, the company’s share price jumped and official disclosures showed executives cashing in their shares for millions of dollars.

“As long as stocks are sold after public announcements – and not before – one might conclude that for an executive with significant net worth tied up in the company, it’s a prudent thing to do,” said Marc Fagel, a former longtime enforcement official with the Securities And Exchange Commission (SEC). “But the optics aren’t great.”

The Moderna vaccine was quick to reach a phase 3 trial, and is seen as a promising contender. But, in some ways, the executives’ stock sales have overshadowed the company’s progress.

Advocates have questioned whether it’s appropriate for executives to privately profit before bringing the vaccine to market, especially when American taxpayers have committed roughly $2.5 billion to the company’s vaccine development and manufacture.

Here’s what NPR’s examination found:

  • Stock Sales Worth Tens Of Millions: Since June 1, NPR has found, company executives have sold roughly $90 million worth of Moderna stock. Rather than put a hold on the trades after facing intense criticism in May, company executives continued to sell.
  • Questionable Modifications To Stock Sale Plans: Moderna says its executives pre-scheduled their stock sales long in advance. Those schedules – known as 10b5-1 plans – can act as a defense to charges of insider trading. But the plans have to be put in place when executives do not have confidential inside information. NPR has found multiple executives adopted or modified their plans just before key announcements about the company’s vaccine. That has raised questions about whether they were aware of nonpublic information when they planned their stock trades.
  • Selling To Zero: Generally, corporate best practices suggest that a company’s leadership should hold on to at least some stock in their company to have “skin in the game.” That way, the thinking goes, an executive has an incentive to improve the company’s performance. As Moderna has been developing its coronavirus vaccine, two executives, including the Chief Medical Officer, have sold all their stock holdings in the company. The General Counsel has sold nearly all of her holdings.

In an interview with NPR, Ray Jordan, Moderna’s Chief Corporate Affairs Officer, said the company has strict internal policies in place to prevent illegal insider trading. For example, Jordan said, the company only allows employees to make changes to their stock sale schedules when they don’t have confidential inside information that could affect the company’s share price.

NPR asked Jordan why Moderna executives modified their 10b5-1 plans just before major announcements. Initially, Jordan said by email, “I believe you must have your dates wrong.”

NPR then provided documentation of those dates from the company’s official disclosures to the government, which Jordan did not dispute.

Jordan then said that even though multiple Moderna executives changed their 10b5-1 plans within one business day of announcements, the company had determined that those executives did not have “material nonpublic information” – a key term for insider trading – when they made those changes.

A spokesperson for the SEC declined to comment for this story.

From a relative unknown, to a key player in the vaccine race

Moderna launched in 2010 with a headquarters based in Cambridge, Mass., focused on using a technology called messenger RNA (or mRNA) to develop vaccines and therapeutics. The mRNA technology has been widely considered innovative, but remains largely unproven. The company has never brought a product to market. In early January, Moderna was trading for under $20 per share, and was valued at around six billion dollars.

Then Moderna announced that it had started collaborating on a coronavirus vaccine with scientists from the National Institute of Allergy and Infectious Diseases, which is led by Dr. Anthony Fauci.

By April, the government had committed half a billion dollars to the Moderna vaccine project as part of Operation Warp Speed.

Since then, the company’s stock price has exploded. Press releases suggesting positive news from the scientific trials, or announcing additional commitments of taxpayer funding sent the share price to a peak of around $95, before dropping to between $60-$70 in recent months. The company is now valued at around $25 billion.

As a result, shares owned by Moderna executives suddenly became much more valuable. And those executives have cashed in tens of millions of dollars worth of stock, according to filings with the SEC.

The bad press and critical comments did not deter continued sales. Since June 1, NPR found, executives sold around $90 million worth of stock.

Public money, private gain

The U.S. government is making massive financial bets on several vaccine candidates. In all likelihood, only some of those vaccine candidates will prove sufficiently safe and effective.

“If the vaccine doesn’t work, you lost a lot of money,” Fauci has said. “But we feel this is serious enough that it’s worth the financial risk.”

But even if taxpayers lose money betting on Moderna, the company’s executives have already made millions.

“The insiders are making plenty of profit and they’re mostly doing it with our money,” said Margarida Jorge, a campaign director with the group Lower Drug Prices Now. “I’m absolutely for deploying public money in the interests of public health and the public good. But we don’t have any commitment from the administration that any of this investment is ultimately going to benefit real people.”

Moderna has argued that the company was only in a position to work with the government on a coronavirus vaccine, because it had spent a decade developing its mRNA technology with the support of private investors.

“The company has been funded over the years by billions of dollars of private investment,” Zaks told the Freakonomics podcast in August. “Those billions created the opportunity for the U.S. government to come in earlier this year and say, ‘I’m going to add some money to the pot to make sure that you get the development for this vaccine right.'”

[But they locked in the Government and its funding for mRNA technology years before SARS-COV2, as shown below, so this was a deliberate lie – S.m]
Trying to resuscitate the company with some archive work?

“Set it and forget it” stock plans

Moderna has offered another defense of those stock sales: the sales, representatives and executives say, were scheduled well in advance, and were unrelated to the market-moving announcements about the coronavirus vaccine. An NPR examination of the company’s financial filings tells a more complicated story.

The schedules are known as 10b5-1 plans. If your stock trades are on autopilot, the idea goes, then you can’t be accused of insider trading. But these “set it and forget it” plans have to be adopted when executives do not have “material nonpublic information,” to use the legal term.

In an interview with CNBC in July, CEO Bancel said he and other executives set up their 10b5-1 plans “a long time ago” – in December 2018 – and “obviously, when we set up those plans, none of us had any idea what was going to happen in 2020.”

In fact, NPR has found, Moderna executives, including Bancel himself, implemented new plans or modified older plans at multiple points in 2020, and right around key announcements related to the company’s vaccine.

On Jan. 21, 2020, for example, Chief Medical Officer Dr. Tal Zaks amended his 10b5-1 plan. (It’s unclear what changes he made.)

Then, on Jan. 22, Moderna first widely confirmed that it was working with the government on a coronavirus vaccine. The following day, Jan. 23, the company announced it had received additional funding to support its coronavirus vaccine development.

NPR asked Moderna whether Zaks might have been aware of the collaboration with the government when he changed his stock trading plan.

“What was known on that particular day or not known, I couldn’t specifically talk to,” Moderna’s Jordan told NPR. But he said that the Moderna legal team only allows employees to change their 10b5-1 plans if they do not possess inside information that could affect the company’s share price.

Later, on Friday, March 13, three Moderna executives adopted new 10b5-1 plans, according to records reviewed by NPR: Zaks, Chief Technical Operations and Quality Officer Juan Andres, and then-Chief Financial Officer Lorence H. Kim. (Kim left the company in August 2020.)

On Monday, March 16 – one business day later – the company announced that it had given a participant the first dose of their vaccine as part of its phase 1 trial. The stock ended that day up 24% compared to the previous day’s close. Moderna was “bucking the trend” of the broader market, which was panicking over coronavirus fears, one CNBC host said at the time.

Timing Of Changes To Pre-Scheduled Stock Sales Raises Questions

Jan. 21 – Chief Medical Officer Dr. Tal Zaks amends his schedule of stock sales, known as a 10b5-1 plan.

Jan. 22 – Moderna widely confirms that it is working on a coronavirus vaccine with the National Institutes of Health. The company’s share price rises nearly 5% over the previous day’s close.

Jan. 23 – Moderna announces new funding from the Coalition for Epidemic Preparedness Innovations.

Mar. 13 – Chief Technical Operations Officer Juan Andres, Chief Financial Officer Lorence Kim, and Zaks adopt new 10b5-1 trading plans.

Mar. 16 – Moderna announces that it provided the first dose of its coronavirus vaccine to a participant in a phase 1 trial. Moderna stock climbs 24% over the previous day’s close.

May 18 – Moderna reports early positive data from its phase 1 trial. The company’s stock ends the day up 20% over the previous day’s close.

May 21 – CEO Stéphane Bancel adopts and amends multiple 10b5-1 trading plans.

May 29 – Moderna announces another milestone in its phase 2 coronavirus vaccine trial.

June 1 – President Stephen Hoge amends his 10b5-1 plan.

Despite the close timing, Jordan told NPR, “by the judgment of the legal team, there would not have been material, nonpublic information known” when executives entered into the new plans.

“Every company and individual is entitled to the presumption of innocence. That said, from the public’s perspective, this trading behavior looks very problematic,” said Taylor of the Wharton School, who first pointed out the timing of these changes to NPR.

“If I put on my SEC enforcement hat, I would certainly be asking, ‘What caused you to change the plan on a Friday?'” said Kurt Wolfe, who works as a defense attorney in securities cases for the firm Troutman Pepper. “I don’t think it’s a good fact pattern.”

On May 21 – in between announcements of major vaccine trial milestones on May 18 and May 29 – CEO Bancel amended and adopted 10b5-1 plans. And on June 1, President Hoge amended his trading plan.

“Amending a trading plan after a positive announcement, like trading after a positive announcement, is only problematic if the executive possesses material, nonpublic information at the time,” said Fagel. “Though repeated or questionably-timed changes to a trading plan will reduce its value as a defense to insider trading.”

Selling to zero

Using these 10b5-1 plans, two Moderna executives – Zaks and Andres – have sold all of their shares in the company. General Counsel Lori Henderson has sold nearly all of her shares.

In fact, roughly every week since June, Zaks has exercised stock options (meaning, he bought stock at a price set by the company as part of his compensation), and then immediately sold all of his shares for a significant profit.

[Isn’t this a great explanation for Bancel’s sales too?! – S.m]


On Aug. 24, for example, Zaks exercised stock options and bought 25,000 shares at bargain prices of between $12 to $21. He then immediately sold all of those shares for around $65 per share. Zaks ended up with a profit of nearly $1.2 million.

SEC filings indicate these trades are made under the 10b5-1 plan he adopted in March.

Selling so much stock can also raise concerns for investors – and the public – about why company leaders would sell now if they expected their vaccine to succeed later. After all, a safe and effective vaccine could send Moderna’s stock to even greater heights.

“It perhaps draws questions about how much they believe in it,” said Wolfe.

If the company does develop a safe and effective coronavirus vaccine, and its stock keeps rising, then “these trades will be water under the bridge,” said Fagel, the former SEC enforcement official.

But, Fagel warns, if the vaccine fails, then SEC regulators and angry investors may come looking for answers. In that case, he said, “both class action litigation and an SEC investigation would seem inevitable.”

NPR revelations end here, we’re actually just starting

So what we’ve learned is that Moderna looks like a stock market operation more than a medical one. The chiefs create momentums and then trade. And they use public money to bet and make billions, but more about that shortly.

This news is actually pretext to get you to know the real history of Moderna, a crux point in modern history in the widest sense. The stock dumping is not really news, it’s been happening for quite a while, indicating a long term strategy and business model, rather than a sudden or impulse move.

The next two older reports from Pharma’s own media – STAT, will cement the certainty that Moderna turned into a stock market bubble long ago, under the helms of Stephan Bancel. They don’t mind having some science to show, but that’s just the bait.

Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups

By Damian Garde for STAT, Sept. 13, 2016

At first glance, Moderna Therapeutics looks like the most enviable biotech startup in the world. It has smashed fundraising records and teamed up with pharmaceutical giants as it pursues a radical plan to revolutionize medicine by transforming human cells into drug factories.

But the reality is more complicated.

A STAT investigation found that the company’s caustic work environment has for years driven away top talent and that behind its obsession with secrecy, there are signs Moderna has run into roadblocks with its most ambitious projects.

At the center of it all is Stéphane Bancel, a first-time biotech CEO with an unwavering belief that Moderna’s science will work — and that employees who don’t “live the mission” have no place in the company. Confident and intense, Bancel told STAT that Moderna’s science is on track and, when it is finally made public, that it will meet the brash goal he himself has set: The new drugs will change the world.

But interviews with more than 20 current and former employees and associates suggest Bancel has hampered progress at Moderna because of his ego, his need to assert control and his impatience with the setbacks that are an inevitable part of scienceModerna is worth more than any other private biotech in the US, and former employees said they felt that Bancel prized the company’s ever-increasing valuation, now approaching $5 billion, over its science.

As he pursued a complex and risky strategy for drug development, Bancel built a culture of recrimination at Moderna, former employees said. Failed experiments have been met with reprimands and even on-the-spot firings. They recalled abusive emails, dressings down at company meetings, exceedingly long hours, and unexplained terminations.

At least a dozen highly placed executives have quit in the past four years, including heads of finance, technology, manufacturing, and science. In just the past 12 months, respected leaders of Moderna’s cancer and rare disease programs both resigned, even though the company’s remarkable fundraising had put ample resources at their disposal. Each had been at the company less than 18 months, and the positions have yet to be filled.

Lower-ranking employees, meanwhile, said they’ve been disappointed and confused by Moderna’s pivot to less ambitious — and less transformative — treatments. Moderna has pushed off projects meant to upend the drug industry to focus first on the less daunting (and most likely, far less lucrative) field of vaccines — though it is years behind competitors in that arena.

The company has published no data supporting its vaunted technology, and it’s so secretive that some job candidates have to sign nondisclosure agreements before they come in to interview. Outside venture capitalists said Moderna has so many investors clamoring to get in that it can afford to turn away any who ask too many questions. Some small players have been given only a peek at Moderna’s data before committing millions to the company, according to people familiar with the matter.

“It’s a case of the emperor’s new clothes,” said a former Moderna scientist. “They’re running an investment firm, and then hopefully it also develops a drug that’s successful.”

Like many employees and former employees, the scientist requested anonymity because of a nondisclosure agreement. Others would not permit their names to be published out of fear that speaking candidly about big players in the industry would hurt their job prospects down the road.

Moderna just moved its first two potential treatments — both vaccines — into human trials. In keeping with the culture of secrecy, though, executives won’t say which diseases the vaccines target, and they have not listed the studies on the public federal registry, ClinicalTrials.gov. Listing is optional for Phase 1 trials, which are meant to determine if a drug is safe, but most companies voluntarily disclose their work.

Investors say it’ll be worth the wait when the company finally lifts the veil.

“We think that when the world does get to see Moderna, they’re going to see something far larger in its scope than anybody’s seen before,” said Peter Kolchinsky, whose RA Capital Management owns a stake in the company.

Moderna
The Moderna offices in Cambridge, Mass.ARAM BOGHOSIAN FOR STAT

Bancel, meanwhile, said he is aware of the criticism of him and has taken some steps to address it. After scathing anonymous comments about Moderna’s management began showing up online, Bancel went to Silicon Valley to get tips on employee retention from the human resources departments of Facebook, Google, and Netflix. But he makes no apologies for tumult past or present, pointing to the thousands of patients who might be saved by Moderna’s technology.

“You want to be the guy who’s going to fail them? I don’t,” he said in an interview from his glassy third-floor office. “So was it an intense place? It was. And do I feel sorry about it? No.”

An ambitious CEO dreams big

Bancel, 44, had no experience running a drug development operation when one of biotech’s most successful venture capitalists tapped him to lead Moderna. He’d spent most of his career in sales and operations, not science.

But he had made no secret of his ambition.

A native of France, Bancel earned a master’s in chemical engineering from the University of Minnesota and an MBA from Harvard in 2000. As Harvard Business School classmates rushed to cash in on the dot-com boom, Bancel laid out a plan to play “chess, not checkers.”

“I was always thinking, one day, somebody will have to make a decision about me getting a CEO job,” he told an audience at his alma mater in April. “… How do I make sure I’m not the bridesmaid? How do I make sure that I’m not always the person who’s almost selected but doesn’t get the role?”

He went into sales and rose through the operational ranks at pharmaceutical giant Eli Lilly, eventually leading the company’s Belgian operation. And in 2007, at just 34, he achieved his goal, stepping in as CEO of the French diagnostics firm bioMérieux, which employs roughly 6,000 people.

The company improved its margins under Bancel’s tenure, and he developed a reputation as a stern manager who got results, according to an equities analyst who covered bioMérieux at the time.

“He doesn’t suffer fools lightly,” the analyst said, speaking on condition of anonymity to comply with company policy. “I think if you’re underperforming, you’ll probably find yourself looking for another job.”

Bancel’s rise caught the eye of the biotech investment firm Flagship Ventures, based here in Cambridge. Flagship CEO Noubar Afeyan repeatedly tried to entice him to take over one of the firm’s many startups, Bancel said. But he rejected one prospect after another because the startups seemed too narrow in scope.

Moderna was different.

The company’s core idea was seductively simple: cut out the middleman in biotech.

For decades, companies have endeavored to craft better and better protein therapies, leading to new treatments for cancer, autoimmune disorders, and rare diseases. Such therapies are costly to produce and have many limitations, but they’ve given rise to a multibillion-dollar industry. The anti-inflammatory Humira, the world’s top drug at $14 billion in sales a year, is a shining example of protein therapy.

Moderna’s technology promised to subvert the whole field, creating therapeutic proteins inside the body instead of in manufacturing plants. The key: harnessing messenger RNA, or mRNA.

In nature, mRNA molecules function like recipe books, directing cellular machinery to make specific proteins. Moderna believes it can play that system to its advantage by using synthetic mRNA to compel cells to produce whichever proteins it chooses. In effect, the mRNA would turn cells into tiny drug factories.

It’s highly risky. Big pharma companies had tried similar work and abandoned it because it’s exceedingly hard to get RNA into cells without triggering nasty side effects. But if Moderna can get it to work, the process could be used to treat scores of diseases, including cancers and rare diseases that can be death sentences for children.

Bancel was intrigued. He knew it was a gamble, he told STAT, “but if I don’t do it, and it works, I’m just going to kick myself every morning.”

And so he became the company’s CEO — and soon developed an almost messianic reverence for the mRNA technology.

Despite having never worked with RNA before, Bancel said he sat around the table with his core team in the early days of the company, dreaming up experiments. As a result, he is listed as a co-inventor on more than 100 of Moderna’s early patent applications, unusual for a CEO who is not a PhD scientist.

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

By Damian Garde, STAT, Jan. 10, 2017

SAN FRANCISCO — Moderna Therapeutics, the most highly valued private company in biotech, has run into troubling safety problems with its most ambitious therapy, STAT has learned — and is now banking on a mysterious new technology to keep afloat its brash promise of reinventing modern medicine.

Exactly one year ago, Moderna CEO Stéphane Bancel talked up his company’s “unbelievable” future before a standing-room-only crowd at the annual J.P. Morgan Healthcare Conference here. He promised that Moderna’s treatment for a rare and debilitating disease known as Crigler-Najjar syndrome, developed alongside biotech giant Alexion Pharmaceuticals, would enter human trials in 2016.

It was to be the first therapy using audacious new technology that Bancel promised would yield dozens of drugs in the coming decade.

But the Crigler-Najjar treatment has been indefinitely delayed, an Alexion spokeswoman told STAT. It never proved safe enough to test in humans, according to several former Moderna employees and collaborators who worked closely on the project. Unable to press forward with that technology, Moderna has had to focus instead on developing a handful of vaccines, turning to a less lucrative field that might not justify the company’s nearly $5 billion valuation.

“It’s all vaccines right now, and vaccines are a loss-leader,” said one former Moderna manager. “Moderna right now is a multibillion-dollar vaccines company, and I don’t see how that holds up.”

Bancel made no mention of the Crigler-Najjar drug when he spoke Monday before a similarly packed room at this year’s J.P. Morgan conference.

His presentation instead focused on four vaccines that the company is moving through the first phase of clinical trials: two target strains of influenza, a third is for Zika virus, and the fourth remains a secret. Bancel clicked through graphs of data from animal studies before hurrying on to tout Moderna’s balance sheet and discuss the company’s cancer vaccines, slated for clinical testing later this year.

When STAT asked Bancel after the presentation about Crigler-Najjar, he deferred to Alexion.

In need of a Hail Mary

Founded in 2012, Moderna reached unicorn status — a $1 billion valuation — in just two years, faster than Uber, Dropbox, and Lyft, according to CB Insights. The company’s premise: Using custom-built strands of messenger RNA, known as mRNA, it aims to turn the body’s cells into ad hoc drug factories, compelling them to produce the proteins needed to treat a wide variety of diseases.

But mRNA is a tricky technology. Several major pharmaceutical companies have tried and abandoned the idea, struggling to get mRNA into cells without triggering nasty side effects.

Bancel has repeatedly promised that Moderna’s new therapies will change the world, but the company has refused to publish any data on its mRNA vehicles, sparking skepticism from some scientists and a chiding from the editors of Nature.

The indefinite delay on the Crigler-Najjar project signals persistent and troubling safety concerns for any mRNA treatment that needs to be delivered in multiple doses, covering almost everything that isn’t a vaccine, former employees and collaborators said.

The company did disclose a new technology on Monday that it says will more safely deliver mRNA. It’s called V1GL. Last month, Bancel told Forbes about another new technology, N1GL.

But in neither case has the company provided any details. And that lack of specificity has inevitably raised questions.

Three former employees and collaborators close to the process said Moderna was always toiling away on new delivery technologies in hopes of hitting on something safer than what it had. (Even Bancel has acknowledged, in an interview with Forbes, that the delivery method used in Moderna’s first vaccines “was not very good.”)

Are N1GL and V1GL better? The company has produced no data to answer that question. When STAT asked about new technologies, Bancel referred questions to the company’s patent filings.

The three former employees and collaborators said they believe N1GL and V1GL are either very recent discoveries, just in the earliest stages of testing — or else new names slapped on technologies Moderna has owned for years.

“[The technology] would have to be a miraculous, Hail Mary sort of save for them to get to where they need to be on their timelines,” one former employee said. “Either [Bancel] is extremely confident that it’s going to work, or he’s getting kind of jittery that with a lack of progress he needs to put something out there.”

Former employees and collaborators who spoke with STAT requested anonymity because they had signed nondisclosure agreements — which the highly secretive Moderna requires even some job candidates to sign.

STAT investigation last year found that Bancel had driven away top talent from Moderna with a culture of recrimination and a caustic work environment, including on-the-spot firings for failed experiments.

The company, based in Cambridge, Mass., seems to have repaired its reputation among many rank-and-file employees, winning workplace accolades from Science Magazine and the Boston Globe, but Moderna has lost more than a dozen top scientists and managers in the past four years, despite its vast financial resources.

A bug in the software

Bancel, a first-time biotech CEO, has dismissed questions about Moderna’s potential. He describes mRNA as a simple way to develop treatments for scores of ailments. As he told STAT over the summer, “mRNA is like software: You can just turn the crank and get a lot of products going into development.”

Related: SOFTWARE OF LIFE™ IS A MODERNA TRADE MARK FOR MRNA. LITERALLY. AND THEY MAKE APPS

It seems clear, however, that the software has run into bugs.

Patients with Crigler-Najjar are missing a key liver enzyme needed to break down bilirubin, a yellowish substance that crops up in the body as old red blood cells break down. Without that enzyme, bilirubin proliferates in the blood, leading to jaundice, muscle degeneration, and even brain damage.

In Moderna’s eyes, the one-in-million disease looked like an ideal candidate for mRNA therapy. The company crafted a string of mRNA that would encode for the missing enzyme, believing it had hit upon an excellent starting point to prove technology could be used to treat rare diseases.

But things gradually came apart last year.

Every drug has what’s called a therapeutic window, the scientific sweet spot where a treatment is powerful enough to have an effect on a disease but not so strong as to put patients at too much risk. For mRNA, that has proved elusive.

STAT
mRNA jabs are “rewriting the Genetic Code” we call it “information therapy” – Tal Zaks (Ted 2017)

Before COVID-19, the company’s secretive nature, and its failure to deliver a functional product, was drawing comparisons to the infamous biotech startup Theranos. Similar to Moderna, Theranos rarely published any peer-reviewed material. Like Moderna, Theranos mastered the networking game, and recruited high profile individuals to its board in order to vouch for the company’s “revolutionary technologies.” Once valued at well over $10 Billion, Theranos collapsed after it was revealed that the company was running a massive fraud scheme, in addition to its failure to implement its promised blood testing technology.

Jordan Schachtel @JordanSchachtelIn 2015, Dr John Ioannidis published a paper calling attention to Theranos & the shady biotech unicorn industry. Moderna is mentioned as a company that is following the Theranos path of zero disclosures, & publishing zero papers on their “innovative” tech. onlinelibrary.wiley.com/doi/epdf/10.11…
April 15th 2021113 Retweets281 Likes

Moderna’s Mysterious Medicines

FORBES EDITORS’ PICK |Dec 14, 2016

Excerpts:

“Now an obscure lawsuit filed in British Columbia in October sheds light on one of Moderna’s key partners, and through it FORBES can reveal details on Moderna’s amazing but still untested technology.

It appears that the first two products Moderna has entered into clinical trials rely on technology from a small outfit in Vancouver, British Columbia, called Acuitas Therapeutics. (Acuitas is so small, in fact, that its worldwide headquarters are in its CEO’s single-family home.)

Almost all medicines either block proteins–the building blocks of life–or, in the case of expensive biotech drugs, are proteins themselves. But Moderna has been promising to hack an entirely different part of life’s cookbook. In order to turn genetic information encoded in DNA into the cellular machines that actually are proteins, living things use a messenger chemical called mRNA.

Creating these mRNA drugs is a big challenge on many levels. For them to work, Moderna needs to deliver mRNA to the body’s cells. By itself mRNA breaks down in the bloodstream. Tiny Acuitas specializes in one method: lipid-nanoparticle delivery systems. Its technology essentially wraps the mRNA into balls of fat that disguise the drug so that the target cells will readily ingest it.

“Although we are small,” says Thomas Madden, chief executive of Acuitas, “I believe the technology we have developed is highly effective.”

The problem for Madden and Moderna is that Acuitas doesn’t actually own the technology it has licensed to Moderna. The tech belongs to a third company, publicly traded Arbutus, which recently decided to terminate the license for the tech that it had granted to Acuitas. That’s why Acuitas filed the lawsuit in British Columbia, to protect the deal it had. Arbutus immediately countersued, claiming its deal with Acuitas didn’t cover Moderna’s medicines.

The legal mess has its roots in Moderna’s 2011 start, when Robert Langer, an MIT professor, Moderna board member and founder of dozens of biotech companies, told Bancel that Moderna was too underfunded and small to create its own delivery system. So Moderna vetted over a dozen external delivery methods for mRNA and settled on at least three. One belonged to Arbutus, but Moderna turned to tiny Acuitas to get access to it.

Acuitas was formed in 2009 by Madden after a merger eliminated his position at Arbutus’ predecessor, Tekmira Pharmaceuticals. After a contentious lawsuit Madden was able to license from his former employer the novel tech he had helped develop, and Bancel claims Moderna chose to work with Acuitas because it had “the people and the capabilities.”

But that doesn’t explain why Moderna–flush with capital–didn’t make sure that sublicensing through Acuitas would be okay with Arbutus before advancing its new drugs into human studies.

Bancel met with FORBES at a Brooklyn coffee shop on a recent Saturday to dispel the implications of the lawsuit. He is dismissive of Acuitas’ technology. “We knew it was not very good,” he says. “It was just okay.”

He further explains that Moderna is in the process of producing its own nanoparticle lipids. One such lipid, N1GEL (called “Nigel” internally), appears to cause less inflammation than Acuitas’ version. Another is being licensed from Merck. Bancel says Moderna has stopped using the Acuitas tech for new drugs.

That still leaves a somewhat messy situation for any Moderna vaccines that are being developed using Acuitas’ tech.

Data from one vaccine is expected early next year. If results are good, it could lead to a sizzling-hot initial public offering, even if the Canadian lawsuit ultimately affords Arbutus bigger royalty payments from Moderna.”

Well, the two tiny Canadian companies mentioned above bring royalties to the Canada’s treasury (should I say The British Crown?), so don’t expect Trudeau to backpedal too soon

AND IF ONLY THEY HUSSLED WITH PRIVATE FUNDS, AS THEY CLAIMED…

Moderna chief keep claiming that they started to use public funds only as a patch on infrastructure, science and funding they’ve built for years.

Wrong!

It’s known that NIH + NIAID have long been one of their main sources for the “lavish funding” mentioned earlier and when they locked in the government support, they actually started to leverage it and attract even more private funds, in an self-feeding loop that created today’s monster-bubble.

Very few people know they even got money from BARDA and DARPA. As in “military funds”.

Remember this lie from earlier?
“The company has been funded over the years by billions of dollars of private investment,” Zaks told the Freakonomics podcast in August. “Those billions created the opportunity for the U.S. government to come in earlier this year and say, ‘I’m going to add some money to the pot to make sure that you get the development for this vaccine right.'”
Watch this claim getting nuked:

Taken from:

This grid above looks familiar to you? It does to me, but it’s not blood from people who underwent Covid genetic therapies, just something similar. Taken from:

KEI asks DOD to investigate failure to disclose DARPA funding in Moderna patents

  by  Knowledge Ecology International (KEI)

Luis Gil Abinader has taken a deep dive into Moderna’s surprising practice of never declaring government funding in its 126 patents and 154 patent applications, despite having had funding from multiple federal agencies.

One outcome of his research is a 25 page report (RN-2020-3) on Moderna’s failure to report funding from DARPA, and a request by KEI to DOD and DARPA to remedy this, including by taking title to patents where disclosures should have been made. (Text of letter below, and PDF version here).

KEI will also send a letter to BARDA. The letter below was addressed to DOD and DARPA, and focuses on their funding.

Context

The obligation to disclose federal funding in patent applications has been subject to presidential executive orders, statutes, regulations and contracts, including those cited and quoted in Abinader’s report. The disclosure clarifies the public’s rights in the inventions and the obligations on the entity getting the money, on everything from the government’s worldwide royalty free license to the public’s march-in rights, obligations to make inventions available to the public on reasonable terms, and additional safeguards that can be exercised by a government inclined to do so.

Secondly, the disclosure changes the narrative about who has financed the inventive activity, often the most risky part of development.

One of the earlier norms on this was Franklin Roosevelt’s Executive Order 9424, on the Establishment of a Register of Government interests in patents.

In 2018, the regulations on disclosure were modified by NIST (see 83 FR 15954), where, among other things, the government gave itself unlimited time to remedy a failure to disclose federal funding, to eliminate one loophole that created an incentive ignore the disclosure requirement.

In the past, the US Department of Defense has taken title to patents where federal funding was not disclosed. See: Campbell Plastics v. Brownlee, 389 F.3d 1243 (Fed. Cir. 2004).

There is more on the broader issue of disclosure of government funding in patents here: https://www.keionline.org/bayh-dole/failure-to-disclose

The research on the Moderna/DARPA funding is outlined in a 25 page August 27, 2020 report by Luis Gil Abinader, titled: “Moderna failures to disclose DARPA funding in patented inventions.” RN-2020-3

Below is the text of the KEI letter to Dr. Mark T. Esper, Secretary of Defense, and Dr. Amy Jenkins, of the Pandemic Prevention Platform for the Defense Advanced Research Projects Agency (DARPA), regarding the apparent failure by Moderna to disclose DARPA funding in patent applications.
PDF copy here:

2020. September 18. DARPA letter to KEI confirming investigation of Moderna for failure to report government funding in patent applications. https://www.keionline.org/33970

2020. September 4. BARDA is investigating Moderna’s failures to disclose BARDA funding in patent applications. https://www.keionline.org/33907

2020. September 2. KEI request to BARDA concerning Moderna obligations to disclose federal funding in patent applications. https://www.keionline.org/33892

2020. August 30. DARPA announces investigation into Moderna’s apparent failures to disclose mRNA vaccine patents. https://www.keionline.org/33832

2020. August 28. KEI asks DOD to investigate failure to disclose DARPA funding in Moderna patents. https://www.keionline.org/33763

2020. August 27. 2020:3 KEI Research Note: Moderna failures to disclose DARPA funding in patented inventions. https://www.keionline.org/rn-2020-3

2020. August 5. BARDA Responds to KEI, Public Citizen Letter Asking BARDA to Enforce Moderna Contract. https://www.keionline.org/33633

2020. August 4. KEI and Public Citizen request BARDA to address Moderna’s noncompliance with COVID-19 vaccine contract term. https://www.keionline.org/33618

2020. July 1. KEI receives seven new contracts for COVID 19 research from BARDA and DOD, including five using “Other Transactions Authority” that weaken or eliminate Bayh-Dole and FAR Safeguards. https://www.keionline.org/covid19-ota-contracts

2020. May 21. Moderna and US Government Funding of its COVID-19 Vaccine Candidate. https://www.keionline.org/33150

MORE Press Coverage

Washington Post
2020. August 28. “Moderna failed to disclose federal support in vaccine patents, researchers say: The company with a leading coronavirus vaccine candidate did not adhere to a law designed to protect public investment.” Washington Post. Christopher Rowland.
https://www.washingtonpost.com/business/2020/08/28/moderna-vaccine-patents-darpa-funding/

Bloomberg
2020. August 29. “Moderna’s Patents Probed by U.S. Defense Department, FT Says.” Bloomberg. Chiara Vasarri. https://www.bloomberg.com/news/articles/2020-08-29/u-s-government-s-darpa-probes-patents-filed-by-moderna-ft

Axios
2020. August 5. “Moderna skirts disclosures of coronavirus vaccine costs.” Axios. Bob Herman. https://www.axios.com/moderna-barda-coronavirus-funding-disclosure-2775a517-a775-485a-a509-b6906c8535a9.html

STAT
2020. September 4. “A second U.S. agency will review if Moderna disclosed federal funding in vaccine patents.” STAT. Ed Silverman. https://www.statnews.com/pharmalot/2020/09/04/moderna-vaccine-darpa-barda-patents-covid19/

2020. August 8. “Moderna failed to disclose federal funding for vaccine patent applications, advocates say.” STAT. Ed Silverman. https://www.statnews.com/pharmalot/2020/08/28/moderna-covid19-vaccine-coronavirus-patents-darpa/

2020. August 4. “BARDA faces pressure to force Moderna to disclose cost details from its Covid-19 contract.” Ed Silverman. https://www.statnews.com/pharmalot/2020/08/04/covid19-coronavirus-pandemic-barda-moderna-vaccine-transparency/

Financial Times
2020. August 29. “US government’s Darpa probes Moderna’s vaccine patents: Researchers accuse biotech company of failing to disclose federal grants in patents which also cover Covid-19 candidate.” Financial Times. Donato Paolo Mancini. https://www.ft.com/content/2be1f87e-9e96-4e23-9cc5-33ba35e50586

National Public Radio (NPR)
2020. August 4. “Prices For COVID-19 Vaccines Are Starting To Come Into Focus.” NPR. Sydney Lupkin. https://www.statnews.com/pharmalot/2020/08/04/covid19-coronavirus-pandemic-barda-moderna-vaccine-transparency/

Health Policy Watch
2020. September 3. “US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding.” Health Policy Watch. Grace Ren.
https://healthpolicy-watch.news/pharma-watchdog-requests-further-inquiries-into-modernas-us-patents/

2020. September 1. “US Department Of Defense Is Investigating Moderna’s Patents For Allegedly Failing To Disclose Federal Support.” Health Policy Watch. Grace Ren. https://healthpolicy-watch.news/usagency-investigating-moderna-for-allegedly/

The Pharma Letter
2020. September 4. “Non-profit says Moderna hid federal funding from patent office.” The Pharma Letter. https://www.thepharmaletter.com/article/nonprofit-says-moderna-hid-federal-funding-from-patent-office

Life Sciences Intellectual Property Review
2020. September 8. “Moderna’s COVID-19 and Zika patent applications to be investigated.” Life Sciences Intellectual Property Review. Muireann Bolger. https://www.lifesciencesipreview.com/news/moderna-s-covid-19-and-zika-patent-applications-to-be-investigated-4183

Law360
2020. September 4. “HHS Unit Probes Funding For Moderna’s Patented Vaccines.” Law360. Kevin Stawicki. https://www.law360.com/articles/1307690/hhs-unit-probes-funding-for-moderna-s-patented-vaccines

2020. August 31. “DOD Investigating Moderna’s Vaccine Patents.” Law360. Kevin Stawicki. https://www.law360.com/compliance/articles/1305849/dod-investigating-moderna-s-vaccine-patents

2020. August 28. “Activists Say Moderna Hid Gov’t Support For Vaccine Patents.” Law360. Kevin Stawicki. https://www.law360.com/articles/1305474

Moderna’s vaccine was developed with support from the NIAID, and, as covered in a past fact check, analysis from Axios found that the National Institutes of Health, of which the NIAID is part, may own intellectual property used in producing Moderna’s vaccine. Dr. Francis Collins, director of NIH, has also said that NIH has a stake in intellectual property used in the vaccine, though what exactly this means in practical terms is unclear. 

The Dispatch Fact-check

Also…

All the documents Glenn Beck is creaming about and more can be found below:

Nipah virus as in…?

READ: URGENT! DEBUNKING THE NEXT ENGINEERED PANDEMIC: HEMORRHAGIC FEVER (NIPAH, MARBURG, EBOLA)

Well, yeah, no coincidence here either, more proof to that below.

SO WE HAVE A FINACIER WHO TOOK OVER A WELL FUNDED PHARMA START-UP AND BROUGHT IN HUGE FUNDS, IGNITING THE MOTHER OF ALL ENRONS. WHO’S THIS GUY?!

Buckle up, friends, this so far was jus the prelude.

Bancel came to Moderna from the French Merieux Institute.

Merieux happens to be the French billionaire who helped China build the infamous P4 Lab in Wuhan.

Merieux also happens to be an old friend of Xi’s.

That Xi visit at the Merieux HQ in France happened in 2014, not long after this:

Obama & Xi working together on a pandemic playbook in 2012

And then, in 2018..

2017

Bancel maintained a top role in the Merieux Foundation long after leaving the BioMerieux division for Moderna.

CA Merieux Foundation

Therefore no surprise that Moderna was allegedly the first to get the SARS-COV2 genetic code and start working on the mRNA injection.

CONFIDENTIAL DOCUMENTS: MODERNA SENT A MRNA CORONAVIRUS VACCINE CANDIDATE TO UNIVERSITIES WEEKS BEFORE EMERGENCE OF COVID-19

MORE COINCIDENCE THEORIES

In 2017, Moncef Slaoui, the brain behind GSK, also took a seat on the board of Moderna,

Trump awarded Moderna almost $0.5Billion from public money a few days before nominating Slaoui as Warp Speed co-chief. in May 2020.

Trump’s Moroccan “vaccine czar”: worked for Bill Gates, Google, GSK. Worked in China. Transhumanist. Lockdown fanatic

“Valera’s efforts (Moderna subsidiary) have resulted in the demonstration of preclinical efficacy of Moderna’s mRNA-based vaccines in multiple viral disease models, Moderna said.

In the partnership with the Gates Foundation, Valera will apply its mRNA vaccine platform as well as Moderna’s drug platform Messenger RNA Therapeutics™. Designed to produces human proteins, antibodies, and entirely novel protein constructs inside patient cells, the therapeutics are secreted or active intracellularly.” – Genetic Engineering & Biotechnology News

To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus.
He stepped down but he didn’t give up his stakes in Moderna, as the Daily Beast reports:

“Slaoui’s ownership of 156,000 Moderna stock options, disclosed in required federal financial filings, sparked concerns about a conflict of interest.
Democratic Massachusetts Senator Elizabeth Warren called Slaoui out over the matter on Twitter: “It is a huge conflict of interest for the White House’s new vaccine czar to own $10 million of stock in a company receiving government funding to develop a COVID-19 vaccine. Dr. Slaoui should divest immediately.”
The company’s shares skyrocketed last month after news broke of the $483 million in federal funding to work on a coronavirus vaccine.
Slaoui could not immediately be reached for comment on the matter.”

Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation

Gates, Fauci and Slaoui have long been making and selling scandalous vaccines together. It’s a cartel

So we should add Bancel to this cover graphic
DAVOS 2022: BANCEL AND FAUCI MEET AGAIN TO WHINE ABOUT THE ANNOYANCE WE ARE TO THEM. MORE TO COME, SCUMBAGS!

LAST MINUTE:

The circle has just closed.
Unless China faked another interview to prop up another myth.

So this has never been about health, just a global scale racketeering operation that’s coming to light about about to go bust. You can speed up this process simply by spreading this expose far and wide!

UPDATE MARCH 21, 2022: VOILA!

Via our ex-BlackRock friend Edward Dowd. I rest my case, but I bet they will “unrest” it soon.

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER

Only days ago, Luc Montagnier was up in arms on the barricades against Covidiocracy. Suddenly, he is told to have left the battlefield, in peace, not as a fallen general.
Why such a sudden ‘change of heart’?
This is the question.

Got around doing a little video summary, but the devil is in the details below.

“At the age of 89 (August 18, 1932 – February 8, 2022), Professor Luc Montagnier died at the American Hospital in Neuilly-sur-Seine. Doctor Gérard Guillaume, one of his most faithful collaborators, tells us that he left in peace, surrounded by his children.

He was a biologist and virologist, but also and above all a man of remarkable intelligence, who lived for science. In addition to having been named Nobel Prize for Medicine in 2008 for the discovery of the AIDS virus, he worked alongside the greatest scientific institutes in the world during his life. Emeritus research director at the CNRS, professor at the Institut Pasteur, director of the Center for Molecular and Cellular Biology at Queens College of the City University of New York, director of a research institute at the Jiao-tong University of Shanghai. He supported the Academy of Sciences as well as the National Academy of Medicine through his research for many years. For this, he has received countless awards and accolades.

Despite his advanced age and despite all the criticism he suffered in the autumn of his life, notably from part of the scientific community, Luc Montagnier has always fought for free science. We were lucky enough to be able to welcome him several times at FranceSoir, and would like to give him all the honors that are due to him.” – France Soir

He’s just earned his wings

The official announcements say he died in peace, “surrounded by his youngsters”.

Many call this death ‘sudden’, as in “unforeseen”.

Others. such as myself, have been wondering for long why is he still allowed to roam free and blow the whistle, given his deep involvement with the AIDS scam, his out-spoken anti-Pharmafia stance and, more recently, his total dissidence to the Covid / vaccine narrative.

Rare video from World Health Summit, 2010

“His death took place on Tuesday 8 February, on the same day as the funeral of the Italian biologist Franco Trinca struck down by a very violent and suspicious form of Covid-19 despite being in excellent health and used to take care of himself with a thousand precautions. Trinca had often taken up the complaints of the internationally renowned French scientist who, having worked in the field of vaccines, had denounced the dangers of gene serums based on messenger RNA above all for the risk of creating degenerative brain diseases from prions, as highlighted in our latest investigation.” – VT

OMG OMG!
SOURCE

NO CAUSE OF DEATH PROVIDED



Information surrounding his death are inexistent yet, I’m writing this less than 12h after the official announcement. I will add here anything relevant to it, as much as to why he was a major threat to Pharmafia and the WEF cartel.

UPDATE: Associated Press and thus the global mainstream media finally caught up but still no additional info, just more character assassination rituals.

LAST TIMES HE APPEARED IN PUBLIC:

Four weeks before Montagnier’s death:

“On January 9, Montagnier once again appeared on an international media, the Wall Street Journal, in an editorial titled Omicron makes Biden’s vaccination obligations obsolete, co-signed by American constitutionalist Jed Rubenfeld who another disgraced celebrity: married to Amy Chua, fellow law professor at Yale and author of the world bestseller on the mother tiger, Rubenfeld accused of sexual assaults on female students and suspended by Yale for two years. After the article on the Wsj and before the intervention in Milan, Luc Montagnier appeared last Wednesday in the Luxembourg House of Parliament to support a petition against compulsory vaccination, but his commitment against vaccines began well before the Covid era.” – Italy24 News

So, on January 12, 2022, he concluded his career gloriously participating in THIS INVESTIGATION ON CHILDHOOD COVID VACCINATION BY THE LUXEMBOURG PARLIAMENT

And then…

Three weeks before Montagnier’s death:

January 15th, 2022, at a protest in Milan, Italy:

He seems in pretty good shape to me.

“Luc Montagnier, who in 2009 suggested fighting AIDS with better nutrition, he is experiencing an unexpected return these days, accompanied as always by the American assistant and companion Suzanne McDonnell Long, who was next to him in Milan when he added that it was a crime to give this vaccine to children. As in the past, when Montagnier sold expensive papaya preparations in pharmacies, the problem that the professor does not provide any proof of what he claims. His sentences are not based on any research he has done in recent months or years, but respect for the scientific community is not something that would interest him or his followers.” – Italy24 News

So he almost literally died on the barricades…

Last time I checked…

New evidence, including sworn affidavits from leading experts such as Professor Luc A. Montagnier, has been submitted to the International Criminal Court by lawyers in several countries alleging Government’s across the world and their advisors are complicit in genocide, crimes against humanity and breaches of the Nuremberg Code.Daily Expose

“Attorney Melinda C. Mayne, and Kaira S. McCallum submitted a 27-page ‘Request for Investigation’ to the International Criminal Court (ICC) at The Hague back in April 2021 alleging the UK Government and its advisors were complicit in crimes against humanity in the name of Covid-19.

On the 28th of April 2021, the pair received a formal acknowledgement from the ICC and were assigned a case number – ‘141/21’. Since then the pair have been gathering new evidence to use in their ICC claim and have established connections with lawyers and research scientists from around the world.

A new press release released on the 17th August, which can be viewed here, confirms that the pair have received sworn affidavits from leading experts including research scientist and nuclear cardiologist Dr Richard M. Fleming, the Nobel Laureate virologist Professor Luc  A. Montagnier, and Dr Kevin W. McCairn, a neuroscientist and expert on neurological disease.

Professor Luc A Montagnier, who won a Nobel prize for his work on the HIV virus, claimed in April 2020 that he believed the novel coronavirus was created in a laboratory. Then in May 2021 the expert virologist stated that “Mass vaccinations are a scientific error as well as a medical error. It is an unacceptable mistake. The history books will show that, because it is the vaccination that is creating the variants”.

A new claim has also been submitted to the ICC due to the vast amount of new evidence and information that has come to light in the past few months, and the lawyers say they now have compelling evidence that “the SARS-CoV-2 virus and the Covid-19 ‘vaccines’ are deliberately engineered bioweapons that have been released in two phashes on unsuspecting peoples of the world”.

Attorney Melinda C. Mayne, and Kaira S. McCallum have also confirmed that they have now be joined by lawyers who have filed similar Requests for Investigation to the International Criminal Court, in France, the Czech Republic and Slovakia.

Because of this a letter was sent to the ICC on the 12th August 2021 requesting they all be allowed to submit a joint claim, whilst also submitting preliminary evidence for the allegations common to everyone across the world, and requesting the right to have claims specific to individual countries also investigated by the ICC.” – Daily Expose

They called him a “conspirationist” because he was an early adept of the Chinese lab origin of the virus

KARy MULLIS, THE PCR INVENTOR, DIED JUST A FEW MONTHS BEFORE COVID.
DID MONTAIGNER, THE HIV DISCOVERER, DIE JUST MONTHS BEFORE A BIG AIDS RESURGENCE?

Seven weeks before Montagnier’s death:

Four days before Montagnier’s death:

You’ve seen the increasing media coverage about a new HIV strain, I suppose.

Instead of AIDS, I’d call that, and I’m not the only one, “Vaccine-Induced Auto-Immune Syndrome”, but let’s pretend we go along with the official narrative.

Logically, Montaigner should’ve been the first to summon with the Bat Signal.

That never happened. His death happened.

The day Montagnier died:

This was aired in US on the day Montagnier died.

I think we need a recap. we’ll start here and I will gradually build a picture, come back later:

WUHAN-GATES – 3. “COVID-19 Created in Lab with HIV”. Medicine Nobel confirms Indian Research disclosed by Gospa News

(My excerpts, full story HERE)

Professor Luc Montagnier, Nobel Prize for Medicine 2008, to the microphones of the French podcast, specialized in medicine and health, “Pourquoi Docteur” has torn the veil of silence, has broken the sepulcher of taboos, accrediting the research of the Kusuma School of Biology of New Delhi, withdrawn by the authors but republished worldwide by me on Gospa News and Veterans Today a few days ago and immediately targeted by the skepticism of improvised scientists.

Indian research sensationally withdrawn but recovered by Gospa News

«With my colleague, the biomathematician Jean-Claude Perez, we have carefully analyzed the description of the genome of this Rna virus. We weren’t the first, a group of Indian researchers tried to publish a study showing that the complete genome of this virus that has within the sequences of another virus: that of AIDS. The Indian team retracted after publication. But scientific truth always emerges. The AIDS sequence was inserted into the coronavirus genome to attempt to make the vaccine» said Montagnier.

Luc Montagnier, the French virologist Nobel Prize winner for Medicine in 2008 for his AIDS research

In 7 lines, one of the world’s leading experts in medicine makes “tabula rasa” of somewhat sibylline hypotheses so far promoted by virologists, perhaps even induced by some housekeeper worried about national security in the face of the confirmation of a pandemic capable of causing 120 thousand deaths.

His words carry enormous weight: because in 2008 Montagnier discovered the human immunodeficiency virus HIV as the cause of the AIDS epidemic so much that he won the Nobel Prize for Medicine together with Françoise Barré-Sinoussi and Harald zur Hausen.

«Coronavirus would be a manipulated virus, accidentally released from a Chinese laboratory in Wuhan where the AIDS vaccine was being studied. Professor Luc Montagnier said so» writes the Italian Journalism Agency (AGI), one of the few big media to report the news with prominence.

However, it publishes it with less evidence compared to another article on the statements of the American immunologist Anthony Fauci, director of the American National Institute of Allergy and Infectious Diseases, who persistenly supported the natural origin of the virus.

As we have shown in 12 detailed reports on bio-weapon theory, the United States of America are among the prime suspects, together with China, for this pandemic catastrophe.

It is therefore understandable that the American doctor tries to divert attention from the hypothesis of a pathogen manipulated by bioengineering since the most disturbing experiment was conducted by the biosafety 3 of the Burnett Womack Biohazard center at the Chapell Hill site of the University of North Carolina together with the biosafety laboratory 4 of the Wuhan Institute of Virology.

Not only. The research had been supported by the institute where Fauci works through «grants from the National Institute of Allergy & Infectious Disease and the National Institute of Aging of the United States National Institutes of Health (NIH), the National Natural Science Foundation of China and the USAID-EPT-PREDICT funding from EcoHealth Alliance» as stated in the Abstract published by Nature Medicine published in report no. 9.

The trial led to «building a chimeric CoV with a bat CoV S gene (SHC014) in the backbone of a SARS CoV that has adapted to infect mice (MA15) and is capable of infecting human cells».

Researchers Shan-Lu Liu, Linda J. Saif, Susan R. Weiss and Lishan Su wrote that in a study of February 28, in which, however, they showed some fundamental divergences, equal to 96% for about 5 thousand nucleotides, between that “chimeric” CoronaVirus, that is, created in the laboratory and not existing in nature, and the current real pathogen of the SARS-Cov-2 pandemic, so called from the English acronym of Acute Respiratory Severe Syndrome.

But in the supervirus study conducted primarily in the Chapel Hill laboratories of the University of North Carolina, mention that was also made experiments «similar to those using an HIV-based pseudovirus, prepared as previously described and tested on HeLa cells (Wuhan Institute of Virology) which the ACE2 orthologists expressed».

Despite the difference between Covid-19 and the chimeric supervirus, nothing prevents us from thinking that this “prototype” it was then further modified in one of the US Pentagon’s 25 military laboratories, where highly top-secret projects are also managed directly by the Central Intelligence Agency or in one of the 11 existing in the US territory only (on which we will write shortly), including the National Biodefense Analysis and Countermeasures Center – NBACC of the USAMRIID (US Army Medical Institute of Infectious Diseases) in Fort Detrick, Maryland, closed last July for a mysterious biosecurity loss ever better detailed.

http://www.gospanews.net/en/2020/03/24/coronavirus-bioweapon-7-top-secret-military-missions-in-ukraine-fort-detrick-sigonella-wuhan-and-modena/embed/#?secret=YswmTKBpeG

Or that that highly lethal “chimeric supervirus”, such as Covid-19’s “L” genotype, may have been further processed in the Wuhan Virology Institute itself, around which there have been numerous suspicious deaths (of which we will write shortly), concealed by the proverbial Chinese military secrecy imposed by the risk of a capital punishment for espionage or terrorism.

The BSL 4 biosafety labs of the Wuhan Institute of Virology in China

Montagnier is a famous virologist, he was an illustrious professor and researcher of the Pasteur Institute in Paris (one of the first to elaborate a research on the first CoronaVirus strain of SARS in 2003) but for some years he has been working in the most important research center in Shanghai, the Jiao Tong University.

Therefore he is by no means extraneous to matters connected with China and certainly knows Wuhan’s laboratory strongly desired by the entourage of former president Jiang Zemin, historic leader of the Chinese Communist Party who has become popular in the world for international trials for human rights violations in Tibet and for the nickname “executioner of Tiananmen”.

Now Montagnier not only confirms the validity of the Indian study on the traces of HIV inside Covid-19, reported by me in the essential passages from Gospa News and Veterans Today, but supports the “less serious” hypothesis, namely that of an accidental release of the genetically manipulated virus.

Porquoi Docteur’s scoop with the interview with Montagnier

«The hypothesis is that this virus leaves the Wuhan laboratory. It is a high security laboratory but despite all the virus has escaped from the control of the promoters. The history of the fish market is a beautiful legend but it is not possible that it is only a virus transmitted by a bat, it is probably from this that they started, then they modified it. Maybe they wanted to make an AIDS vaccine using a coronavirus as an antigen carrier. A work of sorcerer’s apprentices can be said. Because we must not forget that we are in the world of nature, there are balances to be respected» said Montagnier peremptorily.

According to the scientist, the altered elements of this virus will however be eliminated as it spreads: «Nature does not accept any molecular manipulation, it will eliminate these unnatural changes and even if nothing is done, things will improve, but unfortunately after many deaths».

Also read: AIDS AND COVID ARE TWO COMMERCIAL BRANDS AND ONE BUSINESS MODEL BY FAUCI

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

I failed to make this video viral twice: in November 2020 and the Spring of 2021. Let’s see how it goes now, too late is usually when truth breaks through, and we live from one missed opportunity to the next psyop until we die still waiting for a savior. We could’ve been our own saviors just by paying attention.

Mirror:

Looks like I have to stress one thing out:

Direct implication: what “authoritative sources” have done so far is not ignorance-based misinformation, but deliberate disinformation.

BONUS:

In case you missed this, it’s the same dude who openly admitted on TED that mRNA jabs re-write the genetic code. At least this one went more viral, but not enough to shut up all the nitwits claiming otherwise.

So no surprise this happened

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Just a quick heads up as many people hurry to cry “victory!” after recent announcements from UK, France, Czech Republic and even Israel.
I can’t fully be with you due to personal issues, but I don’t want to let you fall in another trap and later disappointment either.

https://www.reuters.com/world/europe/france-unveil-timetable-easing-covid-restrictions-2022-01-20/

Israel: “Finance minister calls for end to Green Pass”

https://www.timesofisrael.com/as-serious-covid-cases-near-500-finance-minister-calls-for-end-to-green-pass/

But…

  • Global leaders have been looking at what 2022 might hold for the COVID-19 pandemic at The Davos Agenda.
  • Speakers addressed questions around vaccine equity, the impact on society and economics and whether it might become endemic.
  • Below are some of the key talking points.

SOURCE: WEF

We’re heading towards the third year of the COVID-19 pandemic, which has disrupted lives and livelihoods across the planet and led to at least 5.5 million deaths around the world.

As the Omicron COVID-19 variant surges in many countries – and indeed saw the deferral of an in-person meeting in Davos – the pandemic has been front of mind for many at The Davos Agenda.

So, where is the virus headed? Here’s what speakers from different sectors have said so far this week.

Tackling the COVID-19 pandemic

Xi Jinping, President of the People’s Republic of China, opened this week by reminding us of the work that’s already been done.

“The international community has fought a tenacious battle,” he said.

The global vaccination drive has played a major role in the progress we’ve made so far, with Richard Hatchett, the CEO of CEPI, reminding us of the work of COVAX.

The vaccine-sharing facility, which CEPI co-leads alongside Gavi and the World Health Organization, delivered its one billionth dose of COVID-19 vaccines over the weekend.

The pandemic has impacted every aspect of our lives, though, Israeli Prime Minister Naftali Bennett reminded us – and that has driven the response in his country.

Endemic or pandemic?

The history of infectious diseases can tell us something about the next stages of the pandemic, Anthony Fauci, the Director of the US National Institute of Allergy and Infectious Diseases, explained.

Endemicity would mean ‘a non-disruptive presence without elimination’, he said. Similar to other cold-weather upper respiratory infections or parainfluenzas, he explained.

We’re not going to eliminate this virus, he said.

FAUCI @ WEF’S DAVOS 2022 (starts 6 min in)

Richard Hatchett said his long-term view is that we should anticipate COVID-19 will behave more like flu.

“It will continue to circulate, it will be around, people will get sick and there will be continual evolution of the virus.”

Mike Ryan, the Executive Director of the WHO’s Health Emergencies Programme, struck a cautionary tone though in the Meeting the Challenge of Vaccine Equity session.

“We won’t end the virus this year,” he said. “We may never end the virus. Pandemic viruses end up becoming part of the ecosystem. What we can end is the public health emergency.”

And, in terms of endemic versus pandemic, he was clear. “Endemic does not mean good,” he said, citing the examples of endemic malaria or endemic HIV which kill 100,000s of people. “Endemic just means it’s here forever.”

“What we need to do is get to low-levels of disease incidence, with maximum vaccination of our populations, so nobody has to die.” That’s the end of the emergency, that’s the end of the pandemic, he concluded.

….

And Svein Tore Holsether, President and Chief Executive Officer, Yara International ASA, told us that a move from shareholder to stakeholder capitalism isn’t just needed, it’s expected, he said.

And, sustainability and environmental concerns will remain paramount – particularly in light of COP26.

Our lifestyles and our throwaway culture have exacerbated the climate challenge, Indian Prime Minister Narendra Modi said on Monday. It’s essential we move towards a circular economy, he explained.?

The next steps

The path is unlikely to be smooth though. Beyond the health challenges discussed above – vaccine equity, for example – hurdles need to be overcome in areas from trust to reform in global systems.

Sharan Burrow, General Secretary of the International Trade Union Confederation, explained more about the issue of trust.

And she wasn’t alone. Speakers at the announcement of the Schwab Foundation for Social Entrepreneurship’s Social Innovators of the Year 2022 award were also clear on the issue of trust.

The global community needs to work together, even more than it has already, speakers from across sessions agreed. This is particularly important to ensure the equitable distribution of vaccines, explained President Xi Jinping.

And reform is needed, whether of global financial systems, or the means by which we can equitably produce and distribute vaccines.

And there it goes… Climate-19 in full swing, as I predicted almost 2 years ago

https://news.yahoo.com/german-leader-champions-tack-climate-135118725.html

Also have you seen this below? Well, consider their hopes for vaccination rates have bee crushed by our resistance, hence the delay and later desperation.

VACCINES MAY ACTUALLY END THE PANDEMIC BY JULY, BUT NOT AS YOU THINK

To be updated, most probably.

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER

I didn’t mean for this website to go as basic as this, quite the opposite, but apparently there’s still a huge need for basic stuff for basic people.
And we can’t really advance much without covering the basics properly.

Study: Pfizer, GSK, Eli Lilly Topped Military Industry in Defrauding US Govt (2010)

Here’s an older meme that’s basically a sequel to the one above

Based on this testimony:

Now compare my memes against this Pfizer press release: Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

Not much else to add, besides our motto: “Don’t believe what we say, research what we say!”

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER